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Preface 
The aim of this book is the study of cholestasis from different points of view. 
Cholestasis is one of the most common and devastating manifestations of hereditary 
and acquired liver diseases. Since the importance of the disease has been made aware, 
there have been many research works, providing an increase of information. 
Identification of the molecular defect in cholestasis is not only important for diagnostic
reasons, but also to emphasize that impaired transporter function has pathological 
consequences. Indeed, it is now becoming clear that impaired or down regulated 
transporter function is also involved in the pathogenesis of acquired cholestatic 
syndrome. 
Linked to the diagnosis of cholestasis, an important area to study is the serum bile acid 
profiles. In this sense, a great development of analytical methodologies has allowed 
the relationship between them and the different types of cholestasis to be studied. The 
proper interpretation of serum bile acid profiles provides medical management 
against the disease. 
Different models of induction of cholestasis have been designed in order to deepen
understanding and clarify protective mechanisms, which could contribute to 
improved treatment of the pathology. 
The complete understanding of cholestasis will provide an efficient treatment and an 
overall improvement in the patient life quality.
Dr. Valeria Tripodi and Dr. Silvia Lucagioli
Faculty of Pharmacy and Biochemistry,
University of Buenos Aires,  
Argentina 
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1. Introduction 
Intrahepatitic cholestasis of pregnancy (ICP), also called obstetric cholestasis, is a specific 
liver disease that takes place in the second or third trimester of gestation and spontaneously 
disappears after delivery (Shaw et al., 1982; Brites et al., 1998). Firstly reported by Ahfiled in 
1883, it was after 1950 that the disease began to be considered of significance when several 
clinical cases were studied. It has lastly been highlighted the association of ICP with 
perinatal mortality and morbidity of newborns from cholestatic mothers (Pradhan, 2002). 
For pregnant women with cholestasis, quality of life can be impaired by itching, jaundice 
and fat malabsorption, but the prognosis of the mother is good. However, ICP is a condition 
with possible lethal outcome if it is not handled with care. Therefore, an early and accurate 
diagnosis of a risky pregnancy produced by ICP together with a safe medical treatment are 
essential to improve fetal outcome. (Diaferia et al., 1996; Bacq et al., 1995; Meng et al., 1997; 
Milkiewicz et al. 2002). 
Puritus is usually the chief complaint and generally starts in the palms and soles, progressing 
to the arms and legs and eventually involves the trunk and face. There is additional 
progression from occasional to constant pruritus which can lead to sleep deprivation and 
irritability. Jaundice occurs in approximately 17-75% of ICP cases and telangiectasia and 
palmar erythema may be present in up to 60% of clinical cases (Mullaly et al.2001). It was 
found a weak correlation between bile acid levels and pruritus suggesting that the subjective 
symptom cannot be taken to predict severity of the disease. (Glantz et al., 2004) 
Although it is an interesting matter, severity of maternal signs and symptoms does not seem 
to correlate with fetal prognosis and many obstetric clinics still choose to manage ICP 
pregnancies with expectance. Maternal monitoring of fetal movement has been described as 
normal until a few hours before delivery in cases of subsequent fetal demise. 
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The prevalence of pregnancy cholestasis varies throughout the word being South America, 
specially Chile, the geographical area of higher percentage (12-22%) (Pradhan, 2002). 
The exact pathogenesis of ICP is still unknown being probably of multifactorial causes. 
Genetic studies revealed a positive family history in 33-50 %, the condition is known to 
repeat in 40-70% of pregnancies and it is reported an endemic occurrence showing that a 
genetic factor should be taken into account (Lammert et al., 2000). 
Levels of estrogens could also be involved in the development of ICP. This theory is based 
on the observations that the most common date of presentation of ICP is the third trimester 
of pregnancy when the estrogen levels are highest and is resolved promptly after delivery 
when placental hormones return to their normal levels. On the other hand, obstetric 
cholestasis resembles a similar condition that some women develop while taking oral 
contraceptive pills containing estrogens in the formulation. Moreover, twin pregnancies 
bothly display a higher incidence of ICP and more pronounced rises in estrogen levels 
(Pradham, 2002; Lammert et al., 2000). 
In the pathogenesis of ICP, progesterone and its metabolites seem to play an even more 
important role than estrogens. It is described in the literature the development of ICP 
related symptoms after the administration of progesterone in a woman with a history of ICP 
(Lutz et al., 1969; Mullaly et al., 2001). It was also demonstrated that the profile of 
progesterone metabolites in plasma from patients with ICP is markedly different from the 
profile observed in normal pregnants (Sjövall et al, 1970, Laatikainen et a. 1974; Pascual et al. 
2002). 
Though the pathogenesis of the fetal death in ICP is not fully understood, the action of bile 
acids is strongly suspected to be implicated in mortality. During ICP there are a high bile 
acid levels in ammiotic fluid, cord plasma and meconium increasing the flux of bile acids 
from mother to fetus (Lammert et  al., 2000). In cases of intrauterine fetal loss, observation of 
fetus autopsy is consistent with death from acute intrauterine anoxia. Meconium and bile 
acids, especially cholic acid (CA), have been indicated to induce vasoconstriction of human 
placental chorionic veins in vitro (Serrano et al., 1998) as well as to cause acute umbilical 
vein constriction (Altshuler et al., 1989; Altshuler et al., 1992). Although bile acid 
mechanisms are not yet defined, it is well known their toxic action. Thus, there is some 
experimental evidence that bile acids are involved in the mechanisms triggering fetal 
asphyxia in pregnancies complicated with ICP (Brites, 2002). It was also demonstrated that 
taurocholic acid (TCA), a bile acid increased in ICP, causes a decrease in the rate of 
contraction of rat cardiomyocytes and loss of synchronous beating (Williamson et al., 2001). 
Secondary bile acids, lithocholic acid (LCA) and deoxicholic acid (DCA) which are also 
elevated in patients with ICP, are able to cross the placenta (Heikkinen et al., 1980). These 
compounds have been shown to be fetotoxic in experimental animals causing embrio death, 
birth deformities and fetal growth restriction (Zimber et al., 1990). 
In vitro studies indicate that myometrial cell preparations from ICP women show a more 
intense response to oxytocin stimuli than do cells from healthy women (Israel et al., 1986) 
and an increase of oxytocin-receptor expression after being incubated with CA (Germain et 
al., 2003). These findings could be related with preterm delivery in ICP although the exact 
mechanism of action is still unclear for a complete explanation.  
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2. Diagnosis and treatment 
Usually, diagnosis of ICP is based on pruritus with mild or moderate elevated levels of 
amino transferases and raised total serum bile acids (TSBA) (Reyes et al., 1993). However, it 
is often difficult to accomplish an accurate diagnosis by performing solely routine 
laboratory tests because they are also altered in some other conditions of pregnancy. In fact, 
the existence of subclinical cholestasis during pregnancy may also make difficult the 
diagnosis of the disease. Moreover, pruritus in pregnancy is a common symptom in ICP but 
this evidence is not sufficient to discriminate women with ICP from those with benign 
condition of pruritus gravidarum (Meng et al., 1997, Castaño et al., 2006).  
A number of other disorders may erroneously be interpreted as ICP during pregnancy: skin 
diseases, specific dermatoses of pregnancy, allergic reactions, renal pruritus and 
hematological disorders such as Hodkin´s disease and polycythemia rubra vera (Pusl et al., 
2007). The most sensitive indicator in the diagnosis of ICP is a rise of serum bile acid levels. 
Total serum bile acids in healthy pregnancies are slightly higher in pregnant (6.6 ± 0.8 µM) 
than in non-pregnant women (3.2 ±0.7 µM) (Castaño et al., 2006) but levels up to 11.0 µM are 
accepted as normal in late gestation (Brites et al., 2002). Higher fetal complication rates have 
been associated with TSBA levels  higher than 40 µM (Glanz et al., 2004, Pusl et al., 2007).  
Spontaneous preterm deliveries, asphyxia events and meconium staining of amniotic fluid, 
placenta and membranes increased by 1-2% for each additional µmol/L of total bile acid 
concentrations. However, these events did not increase until bile acid levels exceeded 40 µM 
(Glanz et al., 2004). It is suggested that patients could be expectantly managed when TSBA 
levels remain below 40 µM and when pregnant women refer pruritus it should be surveilled 
with the aid of repeated determinations of serum bile acids.(Glantz et al., 2004) 
Recently, a subgroup of asymptomatic pregnant women with high levels of TSBA, and 
normal liver function tests but not showing pruritus has been classified as asymptomatic 
hypercholanaemic pregnants (AHP) (Castaño et al, 2006; Lunzer et al., 1986; Pascual et al., 
2002; Tripodi et al., 2003). Women with AHP did not differ from normocholanemic women 
respect to clinical, biochemical or perinatal characteristics. AHP does not appear to be a 
clinical entity by itself, but a subgroup of normal pregnancies with higher levels of TSBA 
specially the conjugated dihydroxy serum bile acids (Castaño et al., 2006).  
It has been reported that TSBA levels observed in ICP overlapped with those of healthy and 
AHP pregnant women, making it difficult to obtain a differential diagnosis on the basis of 
TSBA measurements as the key for recognition of the disease (Castaño et al., 2006, Muresan 
et al., 2007). Indeed, ICP may be present without elevated bile acids (Muresan et al., 2007; 
Egerman et al., 2004). It has also been reported that up to 45 % of patients with clinical 
diagnosis of ICP may have normal fasting serum bile acids (Mullaly et al., 2001).  
Therefore a clear question emerges from these observations: the monitoring of the patient 
should be discontinued if the TSBA levels are within the reference values? What happen if 
these levels change over the course of the week of delivery? 
With regard to this point, serum bile acid profile has proved to be more informative than the 
determination of TSBA (Baqc et al.; 1995, Meng et al., 1997; Castaño et al., 2006; Lucangioli et 
al., 2009). Although many authors agree on the benefits of evaluating serum bile acids 
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most useful indication in order to diagnose ICP or in establishing adequate bile acids ratios 
to solve how to recognize the disease. One of the reasons of these differences could be 
attributed to different analytical methods reported with the purpose of evaluating the bile 
acid profiles or it could be due to ethnic differences that lead to different bile acid 
prevalences. 
It is important to emphasize that the serum bile acid profile is useful not only to diagnose 
ICP but also to analyze the evolution of the disease after treatment (Castaño et al., 2006). 
The pharmacological treatment of ICP with antihistamine, anion exchange resins and 
phenobarbital to remove peripheral pruritogens has not received wide acceptance because 
of their incomplete efficacy or side effects of therapy (Lammert et al., 2000). Cholestyramine 
is an anion exchange bile acid-binding resin giving some successful results in managing 
pruritus. However, this drug contributes to fat-soluble vitamin deficiency leading to 
postpartum hemorrhage, it does not correct liver enzyme abnormalities and it does not 
improve fetal prognosis in ICP (Mullally et al., 2001). Ursodeoxycholic acid (UDCA), a 
naturally hydrophilic bile acid is presently considered in the treatment of ICP because it 
improves clinical and biochemical parameters in pregnant women. The mechanisms of 
action of UDCA are still under discussion, but there are some evidences of protective  and 
antioxioxidant effects of this bile acid (Lee et al., 1997; Brites, 2002; Copaci et al., 2005). It is 
also known that UDCA therapy alters the hydrophilicity and, therefore, the overall 
distribution of bile acids in the bile acid pool decreasing levels of hydrophobic and toxic bile 
acids as LCA (Lucangioli et al., 2009, Mullally et al., 2001). Moreover, it is known that UDCA 
reverse the impairment in the functionality of bile acid transport across the trophoblast, so 
its administration can be a valuable contribution to the fetal well-being (Serrano et al., 1998). 
On the other hand, UDCA has been shown to improve impaired hepatocellular secretion by 
mainly posttranscriptional stimulations of canalicular transporter proteins leading to 
enhance the elimination of bile acid metabolites and other organic anions as well as mono-
and disulphate steroids (Pusl et al., 2007). UDCA seems to be well tolerated by pregnant 
women and no adverse effect in mothers or newborns has been observed. 
3. Bile Acids: Chemical structure and functions 
Bile acids (BA) are steroid compounds pertaining to hydroxyl-derivatives of 5-cholan-24-
oic acid. They have different physico-chemical properties according to the number, position 
and orientation of their hydroxylgroups, and by conjugation with glycine and taurine, 
glyco-and tauro-derivatives are produced to the liver (Lucangioli et al., 2001). Figure 1    
presents the chemical structures of bile acids showing primary BA like cholic acid (CA) and 
chenodeoxycholic acid (CDCA) and secondary BA, deoxycholic acid (DCA), lithocholic acid 
(LCA) and ursodeoxycholic (UDCA) (Tripodi et al., 2003). Moreover, BA are acidic 
molecules with pka values of 1.5 for taurine derivatives, 4.5 for glycine derivatives and 6 for 
unconjugated BA. 
The biological functions of BA are principally associated with lipid digestion and 
absorption, solubilization of cholesterol and bile formation (Roda et al., 1995). Under 
physiological conditions, serum BA concentrations are normally present at micromolar level 
in the peripheral circulation. However, in hepatobiliary and intestinal diseases, the hepatic 
synthesis and clearance of BA and their intestinal absorption are disturbed, enabling 
quantitative and qualitative changes in the pattern of serum BA (Burkard et al., 2005).  
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(A) UDCA, (B) CA, (C) CDCA, (D) DCA and (E) LCA 
Regarding liver therapy, some BA, like UDCA and CDCA, are administered as therapeutic 
agents in the treatment of cholesterol gallstones. UDCA has also been used in the therapy of 
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biological fluids, and each BA has small structural differences between the others. Different 
analytical methods have been developed for the quantitation of BA in various matrices 
applying separative techniques. In this sense, high-performance liquid chromatography 
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fluids. The HPLC- methods reported involve two chromatographic systems to determine the 
complete BA profile, one for free BA and the other system for BA derivatives (Vescina et al., 
1993). Unfortunately, the combination of HPLC with UV-detection, limited the sensitivity of 
the analysis due to the fact that BA have little chromophorore groups in their molecules 
(Fig. 1).  To improve sensitivity, some derivatization methods have been described by 
Burkard (Gatti et al., 1997). However, these methods are time consuming. In contrast, HPLC 
coupled to mass (MS) detector, represents a sensitive and selective chromatographic 
technique to determine BA in biological matrices. Several MS techniques by ionization have 
been used for BA analysis like HPLC-MS and HPLC-MS/MS, though specially applied to 
the analysis of BA derivatives (Bootsma et al., 1999; Tagliacozzi et al., 2003), being the 
electrospray ionization (ESI) the best detection system. In contrast, unconjugated BA are not 
detectable by MS/MS due to the lack of any specific fragment ions originated from their 
molecules. However, Burkard et al. have developed an HPLC-MS/MS method to quantify 
free and derivatives UDCA, CDCA and DCA in serum. Quantification of unconjugated BA 
was performed using single ion monitoring mode of the deprotonated molecules  (Burkard 
et al., 2005). 
Gas chromatography (GC), has also been applied to the analysis of BA in biological fluids 
(Batta et al., 1999), in some cases, coupling MS as detector (Niwa, 1995; Setchell,et al., 1983). 
However, GC-MS methods are not simple as they require an extensive sample pre-treatment 
like extraction, purification and hydrolysis of conjugated BA and the preparation of volatile 
derivatives prior to detection of all the products (Perwaiz et al., 2010).  
Thin layer chromatography (TLC) is other separative technique applied to the quantitation 
of BA in biological matrix. This technique has used to determine conjugated and 
unconjugated BA, however, UDCA and CDCA cannot be resolved. Brites et al. applied TLC 
in combination with HPLC-UV and GC-MS to quantitate BA in different biological sample 
(Rodriguez et al., 1999). However, TLC is not widely extended in laboratories 
4.1.1 Capillary electrophoresis 
Capillary electrophoresis (CE) is a family of related techniques that employs narrow-bore 
capillaries to perform high efficiency separations of both large and small molecules, 
favoured by the use of high voltages, which may generate electroosmotic  
and electrophoretic flows of buffer solutions and ionic species, respectively, within the 
capillary. 
The CE advantages with respect to other analytical techniques, such as very high resolution 
in short time of analysis, versatility, the possibility to analyze molecules without 
chromophore groups, simultaneous analysis of various compounds with different 
hydrophobic characteristics, small volume of sample, and low cost, have made this 
technique adequate for the analysis of numerous types of compounds like biological 
macromolecules, chiral compounds, inorganic ions, organic acids, DNA fragments and even 
whole cells and virus particles. An increasing number of applications of CE are in progress 
in many clinical laboratories. Significant potential benefits in the future will impact on 
clinical diagnosis and therapy. Specially, there are several instances in which the limited 
availability of biological fluids significantly preclude the analysis of various relevant 
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biochemical compounds that can be achieved because small volumes of sample are required 
by this technique. 
Over the last 20 years, capillary electrophoresis has evolved into a powerful analysis 
technique with different applications. Firstly created to be focused on water-soluble ionic 
analysis, CE has grown to a very high degree of development and now it is employed in a 
wide variety of pharmaceutical, biopharmaceutical and clinical applications. Its 
development in today´s world is in the step of miniaturization processes in science and 
technology including analytical chemistry. 
Medical diagnosis and quality control assays are areas that are specially benefited from 
miniaturization. The ability to quantify each time smaller amounts of compounds in 
biological fluids together with the capacity of analytical systems to handle low nanoliter 
sample volumes extremely improve the diagnosis of many diseases. 
The main disadvantage in the analysis of biological samples are the following: a) small 
amounts of biological fluids or tissues available, that usually are not enough to determine 
their components by traditional techniques; b) small quantities of these components that, in 
some cases, are present in trace amounts; c) presence of numerous interferences and d) 
requirement of simultaneous separation and determination of more than one component. 
These are the major reasons for calling this type of sample as a “complex matrix”.  
In clinical applications, the analytical system should be capable of handling nanoliter volumes 
of sample, effective enough to determine analytes at subnanomolar concentrations, and should 
provide high selectivity and successful separations of different molecules in a single run. 
Capillary electrophoresis seems to possess many of the advantages required for a 
nanotechnique employed with clinical purpose. 
A CE system has been developed for the analysis of BA profile in plasma. The CE system is 
based on a micellar electrokinetic chromatography, as a mode of CE, with the use of sodium 
dodecyl sulfate as micellar agent and cyclodextrins (CD-MEKC) (Tripodi et al., 2003) using 
UV detection.  The CD-MEKC system allowed the simultaneous and complete resolution of 
15 BA (taurine, glycine and unconjugted BA) in serum sample in less than 12 min with good 
precision and accuracy using a simple sample preparation (Fig. 2). 
4.2 Enzymatic assay 
Enzymatic methods have been used to determine total BA in biological matrices. A NAD- 
dependent steroid dehydrogenase, oxidizes hydroxycholanoates with formation of NADH, 
which is measured by UV or fluorimetric methods (Griffiths et al., 2010). 3∞-hydroxysteroid 
dedydrogenase is used in clinical chemistry for analysis of plasma BA to monitor changes in 
liver diseases, however, only BA with 3∞- hydroxysteroid in its molecule can be determined.  
4.3 Immunoassays 
Many radioimmunoassay and enzyme immunoassays methods have been applied for 
simple and rapid analysis of common total BA in plasma. An important disadvantage of 
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A): Electropherogram of a serum sample matrix spiked with 15 bile acid standards, 6-10µM 
for free bile acids and 4-6µM for conjugated bile acids. 1: UDCA, 2: GUDCA, 3: TUDCA, 4: 
LCA, 5: CDCA, 6: GLCA, 7: TLCA, 8: GCDCA, 9: CA, 10: TCDCA, 11: DCA, 12: GCA, 13: 
TCA, 14: GDCA, 15: TDCA 
 
B): Electropherogram of a serum sample from an ICP patient. 4: LCA, 5: GLCA, 9: CA, 10: 
TCDCA, 12: GCA, 14: GDCA, 15: TDCA 
Fig. 2. Electropherograms of serum bile acid assessed by capillary electrophoresis 
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5. Clinical interpretation of serum bile acid profile 
Although physicians have so far used TSBA levels in the diagnosis of ICP, there is sufficient 
evidence that they are not efficient enough as it would be expected. A single value of TSBA 
could be replaced by assessing the profile of bile acids or certain ratios calculated between 
certain BA in particular. It is therefore a priority for physicians to take into account these 
results and interpret correctly the laboratory data for a better evaluation and control of the 
ICP disease. However, not all researchers agree on which bile acid provides more 
information, possibly because of methodological differences in addition to ethnic 
characteristics that might have influence on serum bile acid profiles from different 
populations of the world. 
Laatikaimen et al. in 1978 and many other authors later (Laatikaimen et al., 1978,  Brites et 
al., 1998, Bacq et al., 1995) showed a marked predominance of CA in ICP while Castaño et al  
(2006) demonstrated the presence of LCA as the preponderant bile acid in this disorder. 
Brites et al. in 1998 showed that elevations of glycocholic acid provide a sensitive 
biochemical test for the diagnosis of ICP with 95 % efficiency but state that TCA is even 
better having 100% efficiency (Brites et al., 1998). There are several reports which have 
demonstrated that different ratios calculated from individual bile acid determinations are 
useful in the comprehension of different types of liver diseases (Brites et al., 1998, Azer et al., 
1997, Pusl et al.,  2007). Heikkinen in 1983 and later Brites in 1998 (Heikkinen, 1983; Brites et 
al., 1998) demonstrated that the CA/CDCA ratio is increased in ICP approximately from 4:1 
to 8:1 respect to normal pregnancies.  
Brites et al (1998) employed HPLC for conjugated bile acids analysis and TLC for free bile 
acids, highlighting that free UDCA was not quantified because it did not separate from 
CDCA during TLC separation. On the basis of this methodology the authors established that 
better criterium to diagnose ICP is TSBA >11µM, CA/CDCA >1.5, %CA>42%, 
Glycine/Taurine <1 and GCA/TCA>2. 
However, a latter report has recently determined that CA / CDCA ratio contribute little to 
the diagnosis of ICP (Huang et al., 2009). Using capillary electrophoresis as analytical 
technique, it has been demonstrated not only that CA/ CDCA ratio was below the unit but 
also a shift towards a hydrophobic composition with higher levels of LCA and free bile 
acids was found in women with ICP concluding that LCA is a useful parameter in the 
differential diagnosis of ICP and AHP (Castaño et al., 2006). 
With regard to the analysis of serum bile acids it was found that AHP women showed TSBA 
levels above the usually accepted cut-off values and their serum bile acid profiles 
demonstrated that UDCA levels were higher in AHP patients compared to normal pregnant 
women and to all ICP patients before treatment, with either low or high score pruritus (table 
1). Moreover, in AHP patients LCA levels showed no difference with values of normal 
pregnant women (Castaño et al., 2006). An inspection of the UDCA /LCA ratio, the highest 
value was observed in AHP patients because of the increment of UDCA levels observed in 
these patients. It could be possible to hypothesize that this high ratio has a protective effect 
in AHP patients since they do not develop ICP even with elevated TSBA and it is possible 
that UDCA/LCA ratio could have a higher discrimination power than individual bile acid 
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Total SBA (µM) 3.2 ± 0.7 6.6 ± 0.8 21.9 ± 3.2 29.5 ± 3.3 
LCA (µM) 0.05 ± 0.06 0.3 ± 0.2 0.10 ± 0.03 8.2 ± 1.7 
CDCA (µM) 0.9 ± 0.4 0.7 ± 0.3 3.3 ± 2.1 4.2 ± 0.9 
DCA (µM) 0.2 ± 0.1 1.3 ± 0.7 4.0 ± 1.2 4.9 ± 1.1 
CA (µM) 0.7 ± 0.4 0.7 ± 0.1 1.1 ± 0.7 3.6 ± 0.8 
UDCA (µM) 0.9 ± 0.3 4.5 ± 0.9 13.3 ± 1.9 8.5 ± 1.6 
Free/conjugated 1.1 ± 0.3 0.05 ± 0.02 0.3 ± 0.1 1.3 ± 0.3 
Taurine/Glycine 5.0 ± 0.2 5.6 ± 0.2 6.7 ± 0.2 5.7 ± 0.1 
Table 1. Comparison of TSBA levels and SBA profiles in different groups studied. Results 
are expressed as means ± SEM. Bile acids are expressed in their free, glycine and taurine 
forms. From reference Castaño 2006. 
Later, the same authors (Lucangioli et al., 2009) proposed LCA as an alternative biomarker 
and a more sensitive parameter to evaluate effectiveness of UDCA treatment. It was 
observed a relief of pruritus together with a dramatic decrease in LCA concentrations in all 
patients following UDCA therapy (Fig 3). It was also found that TSBA concentrations 
overlapped before and after UDCA therapy (Fig. 4). Instead, LCA concentrations were high 
in all ICP patients but decreased only in the group of treated patients. Thus, the mentioned 
results indicated that LCA is a more sensitive marker than TSBA to evaluate the therapeutic 












Baseline   Post UDCA
 
Fig. 3. The effect of UDCA therapy in LCA 
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ICP w ith UDCA 0 day
ICP w ith UDCA 15 day
ICP w ithout UDCA 0 day
ICP w ithout UDCA 15 day
 
Fig. 5. Comparison of SBA profiles (mean ± SEM) in normal pregnancies (n = 20) and ICP 
patients with (n =23) and without (n = 5) UDCA treatment. Bile acids are expressed as the 
sum of their free, glycine and taurine forms. *p0.001 (difference in LCA from day 0 to 15 
with UDCA treatment), **p0.03 (difference in DCA from day 0 to 15 with UDCA treatment) 
concentrations obtained in individual SBA did not have any time effect, since SBA profiles in 
ICP patients without therapy did not change during 15 days (Fig 5). This result showed that 
the decrease in LCA and DCA concentrations could be attributed only to UDCA treatment 
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Taurine/Glycine 5.0 ± 0.2 5.6 ± 0.2 6.7 ± 0.2 5.7 ± 0.1 
Table 1. Comparison of TSBA levels and SBA profiles in different groups studied. Results 
are expressed as means ± SEM. Bile acids are expressed in their free, glycine and taurine 
forms. From reference Castaño 2006. 
Later, the same authors (Lucangioli et al., 2009) proposed LCA as an alternative biomarker 
and a more sensitive parameter to evaluate effectiveness of UDCA treatment. It was 
observed a relief of pruritus together with a dramatic decrease in LCA concentrations in all 
patients following UDCA therapy (Fig 3). It was also found that TSBA concentrations 
overlapped before and after UDCA therapy (Fig. 4). Instead, LCA concentrations were high 
in all ICP patients but decreased only in the group of treated patients. Thus, the mentioned 
results indicated that LCA is a more sensitive marker than TSBA to evaluate the therapeutic 
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Fig. 3. The effect of UDCA therapy in LCA 
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Fig. 5. Comparison of SBA profiles (mean ± SEM) in normal pregnancies (n = 20) and ICP 
patients with (n =23) and without (n = 5) UDCA treatment. Bile acids are expressed as the 
sum of their free, glycine and taurine forms. *p0.001 (difference in LCA from day 0 to 15 
with UDCA treatment), **p0.03 (difference in DCA from day 0 to 15 with UDCA treatment) 
concentrations obtained in individual SBA did not have any time effect, since SBA profiles in 
ICP patients without therapy did not change during 15 days (Fig 5). This result showed that 
the decrease in LCA and DCA concentrations could be attributed only to UDCA treatment 





In conclusion, although there is no consensus about which bile acids are better indicators for 
evaluating the ICP, it must be emphasized that clinicians should gradually abandon using 
the value of TSBA determination to assess bile acid profile as a more accurate approach in 
ICP diagnosis and treatment. 
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1. Introduction 
At the end of 1980’s, the introduction of mininvasive surgery in clinical practice represented a 
significant achievement of science and technology research, and laparoscopic cholecystectomy 
(LC) is nowadays considered a gold standard in the treatment of  symptomatic cholelithiasis, 
according to well known and acknowledged advantages. Although experience is essential to 
avoiding rates of morbidity in any surgical procedure, in LC the effect of the learning curve 
does not seem to be the most important factor in minimizing the possibility of iatrogenic bile 
duct injuries (IBDI) because most of them are related to anatomic misdiagnoses and lapses 
from basic principles of biliary surgery. IBDI are still a severe complication of biliary surgery, 
characterized by high morbidity and in some cases significant mortality, often due to the onset 
of septic complications. They cause a costs rise, related to diagnostic and therapeutic 
procedures, and they are often associated with distressing litigations, frustrating for surgeons. 
Factors that may be related to IBDI include certain pitfalls believed to be inherent in the 
laparoscopic approach: the two-dimensional view and the absence of tactile sensation. 
However, an analysis of literature until 2005 shows that the “mini-invasive” approach is 
related to a higher incidence of iatrogenic bile duct injuries (IBDI), both of the main and 
accessory bile ducts. In 2002 Nuzzo (Nuzzo, 2002), by the means of an Italian survey, proved a 
three times higher incidence of IBDI than in open cholecystectomy (OC), showing about 300 
bile duct injuries out of every 100000 cholecystectomies per year in Italy, pointing out in that 
country a considerable mortality, in most of cases related to sepsis, with a significant rise of 
morbidity and healthcare costs ensuing from hospital stay, instrumental investigations, and 
medium and long-term clinical follow-up. Moreover, IBDI are reported to have late severe 
aftermath, causing the surgeon frustration and expensive litigation. After accomplishing a 
learning curve for mini-invasive approach, led by an experienced surgeon, the most significant 
etiopathogenetic factors of IBDI are the misidentification of the main biliary tree (BT) and 
wrong manoeuvres to manage bleedings. Treatment of IBDI requires a multidisciplinary 
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1. Introduction 
At the end of 1980’s, the introduction of mininvasive surgery in clinical practice represented a 
significant achievement of science and technology research, and laparoscopic cholecystectomy 
(LC) is nowadays considered a gold standard in the treatment of  symptomatic cholelithiasis, 
according to well known and acknowledged advantages. Although experience is essential to 
avoiding rates of morbidity in any surgical procedure, in LC the effect of the learning curve 
does not seem to be the most important factor in minimizing the possibility of iatrogenic bile 
duct injuries (IBDI) because most of them are related to anatomic misdiagnoses and lapses 
from basic principles of biliary surgery. IBDI are still a severe complication of biliary surgery, 
characterized by high morbidity and in some cases significant mortality, often due to the onset 
of septic complications. They cause a costs rise, related to diagnostic and therapeutic 
procedures, and they are often associated with distressing litigations, frustrating for surgeons. 
Factors that may be related to IBDI include certain pitfalls believed to be inherent in the 
laparoscopic approach: the two-dimensional view and the absence of tactile sensation. 
However, an analysis of literature until 2005 shows that the “mini-invasive” approach is 
related to a higher incidence of iatrogenic bile duct injuries (IBDI), both of the main and 
accessory bile ducts. In 2002 Nuzzo (Nuzzo, 2002), by the means of an Italian survey, proved a 
three times higher incidence of IBDI than in open cholecystectomy (OC), showing about 300 
bile duct injuries out of every 100000 cholecystectomies per year in Italy, pointing out in that 
country a considerable mortality, in most of cases related to sepsis, with a significant rise of 
morbidity and healthcare costs ensuing from hospital stay, instrumental investigations, and 
medium and long-term clinical follow-up. Moreover, IBDI are reported to have late severe 
aftermath, causing the surgeon frustration and expensive litigation. After accomplishing a 
learning curve for mini-invasive approach, led by an experienced surgeon, the most significant 
etiopathogenetic factors of IBDI are the misidentification of the main biliary tree (BT) and 
wrong manoeuvres to manage bleedings. Treatment of IBDI requires a multidisciplinary 





because in most cases the proper repair represents often the ultimate intervention to the 
patient. Whenever a surgical treatment is required – for “major” injuries – 
hepaticojejunostomy represents the best choice, but options are described as T-tube drainage, 
liver resections and even liver transplantation, confirming their potential extreme seriousness. 
Patients undergoing reparative interventions, following IBDI, require frequently a cholestasis 
evaluation by long-term clinical, biochemical and imaging follow-up (> 10 years), because of 
the possible onset of long term complications (anastomotic strictures, secondary biliary 
cirrhosis), that produce a significant growth of expenditures. Authors performed a meta-
analysis of most recent reviews articles of the last five years, with the aim of assessing the real 
incidence of this issue during these late years. 
2. Methods 
A Pubmed database search was performed to identify the most recent articles from 2006 to 
2011, about IBDI following cholecystectomy, using the keywords “laparoscopic 
cholecystectomy”, “small-incision cholecystectomy”, “open cholecystectomy”, “iatrogenic 
bile duct injuries”, “biliary fistulas”, “iatrogenic biliary strictures”, and “cholestasis”. 
Additional papers, among the most important and cited in literature, reporting incidence of 
BDI following LCs, were individually searched for, excluding case report articles. These 
data are purely descriptive and no statistical analysis was performed. We excluded “Single-
Port cholecystectomy” from our research. By the means of this research, authors examined 
the incidence, the main risk factors, the mechanisms of bile duct injuries, the diagnostic 
work-up and the management, in order to provide the most recent results about this issue. 
3. Classification of IBDI 
At present several classifications of IBDI have been proposed with the aim of standardizing 
the assessment, planning treatment and evaluating the outcome. Nevertheless, none of these 
have been universally accepted as a standard. Some of these classifications are based on the 
anatomical level of the lesion (Strasberg et al., 1995), (Bismuth, 1982), (Neuhaus et al., 2000), 
(Csendes et al., 2001), (McMahon et al., 1995), (Siewert et al., 1994), (Frattaroli et al., 1996) and 
(Bergman et al., 1996) and on the kind of repair required. On the other hand, other 
classifications - (Bektas et al., 2007), (Lau & Lei, 2007), (Kapoor, 2008),(Stewart-Way, 2004) - 
also assess hilar vascular lesions associated in IBDI, which could jeopardize their management 
and overall morbidity. None of them include factors such as sepsis, haemodynamic status or 
comorbidities, which affect remarkably long-term outcome. The most commonly used is 
Strasberg classification (1995), which incorporates the previous classification of Bismuth (1982). 
The development of these two classifications kept up with the operative technique, because 
thanks to LC, IBDI became more complex and more proximal than in OC, so requiring an 
assessment both of site and type of lesion, from the transection through wrong closures, up to 
strictures. The authors prefer Strasberg classification not only for its feasibility to figure out the 
proper treatment, but also because most vascular injuries occurring in LC don’t modify the 
repair technique of the biliary tree. Type A injuries include cystic duct leakage or leakage from 
canalicula in the liver bed, and these can be treated by endoscopy (papillotomy and 
prosthesis). Type B consists of partial occlusion of the biliary tree, mainly caused by the closure 
of an aberrant right hepatic duct. Type C includes the transection without ligation of the 
aberrant right hepatic duct. Type D describes partial damages to a major hepatic duct. Types E 
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injuries are further subdivided into E1 through E5 according to the previous Bismuth 
classification: E1, transection of bile duct > 2 cm from the hilum; E2, transection of bile duct < 2 
cm from the hilum; E3 and E4 represent stricture at the same level or above the confluence of 
hepatic ducts; E5 injuries describe involvement of an aberrant right sectoral duct injury 
concomitant with a common hepatic duct stricture. 
 
Author Year Incidence Operations 
Giger 2006 0,3 22953 
Koulas 2006 0,1 925 
Plummer 2006 0,02 350 
Nickkholgh 2006 0,09 2130 
Tan 2006 0,5 202 
Ledniczky 2006 0,1 1002 
Hussain 2006 0,4 725 
Yüksel 2006 0 74
Wenner 2006 0 338 
Sarli 2006 0,16 2538 
Velanovic 2006 0,25 3285 
Hobbs 2006 0,26 19414 
Santibane 2006 0,14 6107 
Boddy 2007 0,4 4139 
Karvonen 2007 0,38 3736 
Lien 2007 0,12 5200 
Cai 2007 0 629 
Marakis 2007 0,16 1225 
Yegiyants 2008 0,03 3042 
Ibrahim 2008 0,4 1000 
Malik 2008 1,67 1132 
Yaghoubian 2008 0,7 2470 
Georgiad 2008 0,69 2184 
Veen 2008 1 1254 
Tantia 2008 0,39 13305 
Avgerinos 2009 0 1046 
Machi 2009 0 1381 
Triantafylli 2009 0,1 1009 
Priego 2009 0,3 3933 
Sanjay 2010 0 447 
Yamashita 2010 0,58 n.d 
Zha 2010 0,085 13000 
Al-Kubati 2010 0,4 336 
Ghnnam 2010 0,6 340 
Gurusamy 2010 0,95 451 
Keus 2010 0,7 2139 
Giger 2011 0,3 31838 
Pfluke 2011 0 65 
Hamad 2011 0,18 2714 
Harrison 2011 0,25 234220 
Harboe 2011 0,2 20307 
Stanisić 2011 0,2 386 
Table 1. Incidence of IBDI reported in the literature from 2006 to 2011. Median incidence: 
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4. Analysis of IBDI incidence 
Since its introduction over 20 years ago, population-based studies have reported a 
significant increase of IBDI incidence following LC, compared to open technique, ranging 
from 0,1% to 1,7%. About this issue, in Italy Nuzzo (Nuzzo et al., 2002) reported a three 
times higher incidence (0,3% vs 0,1%) compared to the conventional approach. 
Consequently, IBDI during LCs became an important issue in the field of surgical pathology. 
Although there was no evidence of superiority over open technique, soon after its 
introduction LC became the standard treatment of cholecystectomy (NIH Consensus 
Conference 1993). The rising popularity was based on assumed lower morbidity and 
complication proportions, and a quicker postoperative recovery compared to open 
technique (Sheha, 1996). However, the reviewed studies were non-randomised trials, with 
no fair assessment of the effects of the interventions. Authors carried out a survey of studies 
published from 2006 to 2011 (Table 1) (Figure 1), showing in the several surgical experiences 
an higher incidence during the early stage of learning, a following period of stabilisation, 
and an eventual decrease when the amount of LCs rose (Figure 2). In disagreement with this 
point of view, Giger (Giger, 2011) in a retrospective ten years survey (from 1995 to 2005) did 
not report a decrease of IBDI rates (0,3%), in spite of the assistance of the intraoperative 
















































Fig. 2. IBDI incidence: relationship with surgical experience 
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several studies (with no statistical evidence) hypothesize  that the regular practice of critical 
view of safety (CVS)- a codified dissective technique showing the anatomic elements of 
Calot’s triangle- could cause a decrease of IBDI rates (Yamashita 2010, Yegiyants 2008, 
Avgerinos 2009, Sanjay 2010). Instead, Strasberg himself mentioned the lack of evidence of 
CVS for preventing IBDI, although surely a great step toward a safer LC, but it is unclear 
whether the CVS alone is sufficient as a technique to minimize the risk of IBDI. Also, by way 
of example, major IBDI continue to occur in the Netherlands despite increasing adoption of 
the CVS technique (de Reuver, 2007). Gurusamy (Gurusamy, 2010),  in a meta-analysis of 
randomized clinical trials of LCs for acute cholecystitis, reports lower IBDI rates in early 
treted patients (0,5%) compared to delayed interventions (1,4%). Minor IBDI rates are also 
decreased according to Yüksel (Yüksel, 2006) (3% vs 4,6%). Boddy (Boddy, 2007) in a ten 
year series of 4139 LCs, reported lower rates of IBDI for hepatopancreaticobiliary surgeons 
(0,1%) in comparison to general surgery consultants (0,9%). Another controversial factor is 
the use of IOC: some authors recommend its routinary employment (Nickkholgh, 2006 - BDI 
0,09%), others (Sarli, 2006) report no disadvantages with a selective use (IBDI 0,16%). About 
the influence of workload on surgeons efficiency, Yaghoubian (Yaghoubian, 2008) reports a 
decrease from 1% to 0,4% of IBDI, after implementation of the 80-hour workweek in his 
hospital. Two studies examine surgeon’s experience as factor affecting IBDI incidence: 
Hobbs (Hobbs, 2006) reports a decrease of IBDI from 1994 to 1998 (from 0,35% to 0,13%), 
ascribing 1/3 of IBDI of his centre to surgeons with < 200 operations in the previous 5 years ; 
Harrison (Harrison, 2011), after analysing a 234280 LCs series, does not report any 
difference (IBDI 0,24% vs 0,26%) between rates of experienced surgeons compared to 
residents. Concerning the surgical approach, Keus’ (Keus, 2010) Cochrane Review compares 
open, small-incision, and laparoscopic cholecystectomies, evaluating only randomized trials. 
In this study there is no statistical evidence of IBDI rates among the three approaches, with 
laparoscopic IBDI rates that range from 0,2% to 1,4%. However, the trials analysed in the 
review, statistically compelling, do not include acute cholecystitis as indication, but embrace 
minor injuries in IBDI rates, as self-limiting bile leakage, whereupon rates are as high as 
1,4%. Intraoperative ultrasonography (IOUS) seems to be an effective tool in reducing IBDI 
rates (Machi, 2009 -  BDI: 0%, 1381 LCs), but unfortunately there are few studies about this 
technique, which requires a long learning curve (according to the author, > 100 procedures) 
discouraging its widespread. As one can infer from Table 1, showing incidences from the 
total amount of 412585 LCs performed in several international centres, the median estimated 
incidence is 0,2%, certainly lower than those reported before 2006. Nevertheless, it’s difficult 
to establish if currently this value of incidence is equal to that reported in OCs, sometimes 
reported as low as 0,1%. In conclusion, according to authors’ analysis, it seems that during 
the last years IBDI incidence following LCs is lower than that reported in the previous 
fifteen years since the approach was introduced in 1987. This occurrence could be related to 
the wider experience of the several centres, to the spread of better technologies, and likely a 
greater concern and a careful sensitivity of surgeons’ community toward this issue. 
5. Risk factors 
Several risk factors are related to IBDI, which can be classified as patient factors, local factors 
due to illness, and extrinsic factors, related to the surgeon and his operative technique. 
Patient factors are male gender, advanced age and obesity (Waage, 2006). Local factors 
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anomalies of the biliary tract (BT) (Colovic, 2009), concerning both the proximality and the 
confluence between the cystic duct and the main BT, which may be angular (75%), parallel 
(20%) or spiral (5%), so jeopardizing its dissection (Strasberg, 2008); inflammatory 
conditions, such as acute cholecystitis, that increases up to three times the risk of IBDI with a 
5% rate, are the most important predisposing factor for IBDI in LC (Kitano, 2002). The 
reason of this rate is what Strasberg name “hidden cystic duct syndrome”, or otherwise 
“second cystic duct syndrome”. When the surgeon dissects the infundibulum to identify the 
cystic duct as first step (infundibular technique), without first isolating Calot structures, the 
hepatocholedochus may be confused with a false cystic duct, and sectioned. This 
misidentification is more likely with acute and chronic inflammation, large stones impacted 
in the infundibulum, adhesions between gallbladder and choledochus or intrahepatic 
gallbladder (Chapman, 2003). These last conditions are related to extrinsic factors, too. In 
fact, when anatomy is not clear, dissective technique must be meticulous. So surgeon must 
not only isolate infundibulum, but  also accurately prepare Calot triangle before cutting any 
structure, in order to avoid IBDI. In LC they are more proximal, and sometimes associated 
with vascular injuries, often depending on the right hepatic artery. The incidence of vascular 
injuries during LC is 61% in the series by Koffron (Koffron, 2001) and 47% in the series by 
Belghiti (Alves, 2003). It is still controversial the possible influence  of the associated 
vascular lesion on the outcome of the surgical biliary diversion. In LC the learning curve 
seems to be the most important factor for minimising IBDI rates (Archer, 2001). Even 
surgeon’s tiredness has been implicated as a risk factor for IBDI (Yaghoubian, 2008), as 
testified by decreased incidence with work hour restrictions. 
6. How to prevent IBDI 
Principles for a correct technique in laparoscopic approach, for preventing IBDI, were 
largely described since the beginning of laparoscopic era. Use of a 30° camera, avoiding 
thermocoagulation near the main BT, a meticulous dissection, an accurate haemostasis and 
eventually conversion to open surgery, whenever is not possible to figure out clearly the 
anatomy, all of these represent well-known and precious dogmas (Troidl, 1999). During LC 
correct identification of the cystic duct can made easier in complex cases by several 
methods. Routinely intraoperative Cholangiography (Traverso , 2006) can show the whole 
biliary tract, including any anomaly; it can verify the existence of IBDI, leading quickly to 
treatment. Many authors state that unfortunately many lesions have already been made at 
time of the radiological investigation,  but nonetheless this represent a meaningful step 
because an early diagnosis is helpful in the outcome of repair. The critical view technique, 
described by Strasberg in 1995, consists of the identification of the cystic duct and cystic 
artery through dissection of the upper border of the Calot triangle along the underside of 
the gallbladder, thereby exposing the base of the liver. Once this view has been achieved, 
these two structures will be the only entering the gallbladder. Exposing the inner layer of 
the subserosa could be useful, further optimising the critical view, either for aberrant ducts 
or swollen gallbladder (Mirrizzi, 1932). The infundibular technique is based on the 
identification of the cystic duct where it joins the infundibulum. Some authors still 
recommend this technique, if routinely assisted by the intraoperative cholangiography. It is 
currently the most widely used and maybe quickest technique, but it has the drawback of 
not preventing IBDI because of lacking of the contemporary assessment of cystic duct and 
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main BT (an hot point of the hidden cystic duct syndrome). The Fisher method consists of 
dissecting the gallbladder from the gallbladder bed starting from the bottom to the 
infundibulum, as in open surgery. Since cystic artery is ligated at the end of this step, this 
procedure is more bleeding, thereby more dangerous. The use of intraoperative laparoscopic 
ultrasound represents another method to prevent IBDI. It is a really interesting diagnostic 
tool, even if it requires an equipped operating room and highly trained staff. A multicentre 
study by Machi (Machi, 2009) highlighted his usefulness. However, its advantages are 
unclear compared to the intraoperative cholangiography, neither they submit a 
standardized technique. So its effectiveness has to be demonstrated, because it is more 
expensive than cholangiography, highly operator-dependent and not available in  every 
hospital. 
7. Diagnosis 
Early diagnosis of IBDI is of primary importance, and decisive as well for the long-term 
results after treatment. IBDI are noticed intraoperatively only in few cases, often by means 
of bile leaking, allowing an early repair. Unfortunately, in most cases, at times after days or 
weeks after intervention, diagnosis is accomplished lately, due to the onset of abdominal 
pain, fever, jaundice, and septic syndrome. An unusual postoperative course may be a 
warning sign of IBDI. Postoperative diagnosis must be assessed by clinical exam, lab values 
(cholestasis) and imaging techniques. Liver function tests after bile duct injury may show 
cholestasis by the rise of Gamma-Glutamyl Transpeptidase (GGT) and and Alkaline 
Phosphatase (ALP). However, these tests may often be in the normal range. In patients with 
biliary stricture or complete occlusion, bilirubin is elevated, while in bile leakage, bilirubin 
may be normal or only mildly elevated, after absorption of bile from the peritoneal cavity 
(Lau, 2010). Intraoperative recognition of bile duct injuries and its immediate repair is 
highly advantageous in preventing serious complications (sepsis) and increase repair 
success rates (Lohan, 2005). Unfortunately, diagnosis is intraoperative only in 10% to 30% of 
cases (Lee, 2000), while most of them are recognized postoperatively, with patients 
sometimes complaining of vague abdominal symptoms, 48h after the intervention (biliary 
abdominal collections, jaundice, anorexia, elevation of cholestasis and liver enzyme values) 
(Lillemoe, 2006). Finally, we can have delayed diagnosis for cases that often become more 
complex and with poor prognosis, recognized after a week to months since intervention, 
with recurrent cholangitis, obstructive jaundice up to secondary biliary cirrhosis (Sicklick, 
2005). Ultrasonography is the first investigation which can show fluid collections and 
dilatation of the biliary tract, but reveals neither the site and seriousness of the lesion nor a 
coexisting vascular injury, for what Computed tomography with contrast agent is 
recommended. Scanning with iminodiacetic acid (HIDA scan) can only diagnose bile leaks. 
MR-cholangiography is at present a fundamental investigation that allows to identify leaks 
from small biliary radicals or cystic duct stump, together with the presence of arterial 
injuries and choledocholithiasis. MR- cholangiography with manganese is an efficient 
method to reveal IBDI, but series in literature (Khalid, 2001) are few. Cholangiography, both 
percutaneous transhepatic (PTC) and endoscopic (ERCP), is the gold standard for 
evaluating bile duct injuries, often essential to plan therapeutic procedure. Sometimes they 
represent the ultimate treatment. In cases of lesion proximal to the hilum,  with either 
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Management of bile duct injuries is complex and a multidisciplinary approach in tertiary 
centres is recommended. In any case, early recognition and treatment of septic 
complications is of paramount importance. Management can be categorized into non-
surgical and surgical, and has to be performed in referral centres because often repair 
intervention represents the only chance of care for the patient. The therapeutic approach and 
its timing depend on several factors: the extent of lesion, the experience of the surgeon, the 
inflammatory and haemodynamic status, all of them jeopardize outcome. It is well known 
that, an intraoperative recognition of the lesion and its immediate repair offers the best long-
term results with a low morbidity, reduced hospital stay and costs. The experience of 
referral hepato-biliary surgery centres plays an important role, as demonstrated by the 
better success rates of repair (de Reuver, 2007), especially in case of proximal IBDI 
associated with vascular injury (Bilge, 2003). Non-surgical management is based on 
endoscopic procedures (ERCP) and on interventional radiology, often mandatory for repair 
and less expensive. They require bilioenteric continuity. They are less invasive and more 
appropriate in patients who are not candidates for surgery (Misra, 2004). Recently the 
development of different types of biliary prostheses contributed hugely to simplify the 
management of biliary benign strictures (Ramos-De la Medina, 2008). Endoscopic treatment 
(papillotomy with stenting) is indicated for type A lesions. Its effectiveness decreases if leaks 
are more proximal, because of differences in the basal or intraductal pressure, of CD length 
and BT diameter (Marks, 1998). About surgical management, in case of the complete 
transection of the common hepatic duct or of choledochus, end-to-side Roux-en-Y 
hepaticojejunostomy represents the best bilio-enteric anastomosis. The defunctionalised 
loop avoid intestinal reflux into the BT and prevents ascending cholangitis. The 
hepatoduodenal anastomosis has an increased anastomotic tension and reflux, and a higher 
rate of developing high debt biliary fistula (Mercado, 2008). Still controversial is the 
effectiveness and the duration of a transanastomotic tutor, and it depends on surgeon’s 
experience and choice. In case of complete section, an end-to-end anastomosis on T-tube is 
not indicated because in almost 50% of cases is followed by biliary stricture (Jarnagin , 2009). 
Biliary diversion should be preferred when vascular damage is expected, even if section of 
the bile duct is just partial. A T-tube has therefore only a decompressive function and does 
not act as a tutor for a bilio-biliary hazardous anastomosis; it can therefore be used only in 
selected cases such as partial section or lesion with a proper vascularisation. Finally, 
unfortunately, there are some complications that may require liver transplantation: IBDI 
associated with recurrent episodes of cholangitis, chronic cholestasis and secondary biliary 
cirrhosis, and lesions of the hepatic hilar vessels, especially the hepatic artery, which 
according to some authors can lead to an acute hepatic failure (Fernández, 2004), although 
this occurs rarely in a liver otherwise healthy because of its double blood supply (Stewart , 
2004). 
9. Hepatico-jejunal anastomosis 
A regular evaluation of cholestasis is indicated in patients undergone hepaticojejunostomy, 
by over ten years lasting follow-up due to the potential onset of long-term complications. 
The goal of surgical repair of the injured biliary tract is the restoration of a durable bile flow, 
and the prevention of short- and long-term complications such as biliary fistula, intra-
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abdominal abscess, and subsequently biliary stricture, recurrent cholangitis, and secondary 
biliary cirrhosis. A tension-free Roux-en-Y hepaticojejunostomy is the preferred procedure 
for the majority of bile duct injuries. Tension-free end-to-end anastomoses are rarely 
possible, even if the duodenum has been largely mobilized. Moreover, a high rate of 
restricture has been reported for end-to-end repair of laparoscopic bile duct injuries 
(Stewart, 1995), sometimes up to 100% of cases.  For diathermy injury to the bile duct, the 
anastomosis should be made proximally near to the confluence of the bile ducts to avoid 
stricture formation, as a consequence to coagulation injury to the collateral network of blood 
vessels supplying the CBD/CHD (Lau, 2009). Outcome after HJ is evaluated by cholestasis 
and liver function tests - the clinical presentation of an anastomotic stricture is cholangitis in 
almost half of the case, and jaundice or abnormal liver function tests in the other half 
(Goykhman, 2008), with the potential onset of long-term complications (> 10 years) 
requiring a further intervention, often transhepatic percutaneous stenting. Factors as 
ischemia, inflammation, and fibrosis may play a fundamental role in the development of 
strictures. About long-term out come, a poor prognostic factor is serum ALP levels higher 
than 400 UI six months after intervention (Huang, 2003). Independent poor prognostic 
factors of the HJ outcome are: surgical repair in the presence of active inflammation 
(peritonitis), injuries at or above the biliary bifurcation, and bile duct injury with 
concomitant vascular injury. These factors are associated to a significant higher risk of 
developing severe biliary complications, such as restrictures, hepatic abscess, and secondary 
biliary cirrhosis (Schmidt, 2004). Two thirds of recurrences occur within the first two years 
from the intervention, but stricture recurrence even after 10 years has also been reported 
(Sutherland, 1999). The long interval from reconstruction to symptomatic late stricture and 
liver failure underlines the need for long-term follow-up. 
10. Conclusions 
Analysis of literature related to IBDI following LCs is still difficult and inaccurate, because 
bile duct injuries are not always standardized, according to the several existing 
classifications, and as consequence authors do not always specify the type of injury 
reported. Several papers report laparoscopic techniques with the aim of reducing IBDI, but 
none of them is absolutely perfect or even better than others, because as a matter of fact IBDI 
may occur even to the most skilled laparoscopic surgeons. Accordingly, we might suppose 
that these complications are not exclusively due to unskilfulnes below standards, but they 
are probably related to the limits of the mininvasive approaches themselves – lack of three-
dimensional view and loss of tactile feedback – which could increase operative risks. In 
other words, compared to a recent pastime, from 1987 to 2005, during which IBDI following 
LCs had a huge rise, estimated in Italy as high as between 0,3%vs 0,1% (an amount of 300 
IBDI per year out of every 90000 LCs), according to the most recent literature a decreasing 
trend is reported. Everyone must trust in a leading concept: during the first dissective 
phases, in case of unclarified anatomy, the surgeon must not hesitate about converting, with 
the aim of carrying out a safer intervention, because of the potential hazard of IBDI. LC is 
still an ideal approach for symptomatic cholelithiasis, but a cholecystectomy through a 
“wide subcostal laparotomy” is indicated as well, if preserving from a bile duct injury, 
which is at present a dreadful complication in terms of morbidity, mortality and social costs. 
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most efficient strategy to prevent IBDI. IBDI following LC represent a delicate and 
interesting chapter in hepato-biliary surgery. They are characterized by high morbidity and 
sometimes mortality, especially caused by septic complications. The pastime higher 
incidence seems decreasing and close to that described in traditional surgery, likely due to a 
better knowledge of the mini-invasive approach and an improved sensitivity toward this 
issue by the surgical community. Nonetheless they are still causing an increase in healthcare 
costs because of the investigation, the management and the hospital stay, and moreover for 
legal issues frustrating to surgeons. Among diagnostic tools, MR Cholangiography is 
thought to be very important for a suitable biliary-vascular study, but is often followed by 
second level invasive procedures, that sometimes represent an effective therapeutic option. 
An early diagnosis is directly related to outcome of the repair, that must be 
multidisciplinary – endoscopy, interventional radiology, and surgery – in referral centres, 
because frequently the patient has an unique therapeutic chance. For “major” lesions, 
Hepaticojejunostomy is the intervention of choice, whereas a T-tube diversion is indicated 
for selected patients, because of long-term biliary strictures. A regular evaluation of 
cholestasis is indicated in these cases by means of over ten years follow-up.In case of IBDI, 
irrespective of biliary repair,  the early recognition and treatment of the septic 
complications, that often rise up mortality, is the most important aim on planning  
diagnostic and therapeutic work-up. 
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cholestasis is indicated in these cases by means of over ten years follow-up.In case of IBDI, 
irrespective of biliary repair,  the early recognition and treatment of the septic 
complications, that often rise up mortality, is the most important aim on planning  
diagnostic and therapeutic work-up. 
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1. Introduction  
Acute jaundice due to bile duct obstruction is defined as the retention of bile and bile 
components. Kidney and liver are largely responsible for inactivation and excretion of 
drugs, including organic anions, and other chemicals. In obstructive jaundice, adaptive 
mechanisms may permit urinary excretion of those potentially toxic compounds that could 
not be eliminated by the liver because biliary transport is impaired (Reichen & Simon, 1988; 
Klaassen & Aleksunes, 2010; Hagenbuch 2010). 
A large and diverse number of organic, or weak organic acids that exist as anions at 
physiological pH, are secreted by mammalian renal tubules principally along the 
proximal portion of the nephron. Although this system secretes a number of endogenous 
compounds, it is generally accepted that is particularly important in secreting numerous 
exogenous compounds, including pharmacologically active substances, industrial and 
environmental toxins, and plant and animal toxins (Wright & Dantzler, 2004; G. 
Burckhardt & Pritchard, 2000). The renal organic anion transport plays a critical role, in 
protecting against the toxic effects of these anionic substances, by removing them from the 
blood principally via the organic anion transport mechanisms found in the apical and 
basolateral membrane of renal epithelial cells. Several carrier proteins have been cloned 
and are functionally characterized from both membrane domains of rat kidneys (El-
Sheikh et al., 2008; Wright & Dantzler, 2004). Defining the modifications on the expression 
of these transporters is important, both to understand the cholestatic process and to 
identify potential therapeutic targets. 
Cholestasis has been shown to alter the transport of bile salts and other organic anions 
(Denk et al., 2004; Klaassen & Aleksunes, 2010). The modulation in the expression of renal 
organic anion transporters constitutes a compensative mechanism to overcome the hepatic 
dysfunction in the elimination of organic anions. 
This chapter reviews our current knowledge of the significant roles played by these 
transporters in organic anions elimination, focusing particularly in their renal expression 
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2. Organic anion transporters 
The expression and function of several organic anion transporters in kidneys from rats with 
obstructive cholestasis will be reviewed. These transport proteins are listed below: 
 Organic Anion Transporter 1 (Oat1) 
 Organic Anion Transporter 3 (Oat3) 
 Bilitranslocase (BTL) 
 BSP/Bilirubin Binding Protein (BBBP) 
 Sodium dependent Bile Salt Transporter (ASBT) 
 Organic Anion Transporting Polipeptide 1 (Oatp1) 
 Multidrug Resistance Protein 2 (Mrp2) 
Oat1, Oat3, BTL and BBBP are expressed in the basolateral membranes. BBBP is also 
expressed in apical membrane, together with ASBT, Oatp1 and Mrp2. Their membrane 
localization is shown in Figure 1. 
 
 
Fig. 1. Organic anion transporters in proximal renal tubule cell. For proteins abbreviations 
see the text. 
2.1 Oat1 
Organic anion transporter 1 (Oat1) is a key organic anions/α-ketoglutarate exchanger in the 
energetically linked basolateral entry of organic anions into the proximal tubule cells of the 
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Oat1 is expressed predominantly in the kidneys and weakly in the brain. Oat1 couples 
organic anions entry to dicarboxylate exit (Sweet, 2005; Torres et al., 2008; Brandoni & 
Torres, 2010; G. Burckhardt & B.C. Burckhardt, 2011). This protein has been 
immunolocalized to the basolateral surface of the proximal tubule. Oat1 mediates the 
transport of many compounds (dicarboxylates, nucleotides, prostaglandins, antivirals, loop 
and thiazide diuretics, β-lactam antibiotics, non-steroidal anti-inflammatory drugs, 
including the prototypical substrate of the classical pathway, para-aminohippurate (PAH) 
(Brandoni & Torres, 2010; G. Burckhardt & B.C. Burckhardt, 2011). This has been 
demonstrated in vitro by its heterologously expression following microinjection of Oat1 
cRNA into Xenopus oocytes or transfection of Oat1 cDNA into epithelial cell lines (B.C. 
Burckhardt & G. Burckhardt, 2003; Russel et al., 2002; Van Wert et al., 2010). Eraly et al. 
(2006) have generated a colony of Oat1 knockout mice, permitting the elucidation of the role 
of Oat1 in the context of other potentially functional redundant transporters. They found 
that the knockout mice manifest a profound loss of organic anion transport (e.g. PAH) both 
ex vivo (in isolated renal slices) as well as in vivo (as indicated by loss of renal secretion). In 
the case of the organic anion, furosemide, loss of renal secretion in knockout animals 
resulted in impaired diuretic responsiveness to this drug (Eraly et al., 2006). These results 
indicate an important role for Oat1 transporter in the handling of organic anions by the 
classical pathway. 
Connected to this, we have reported an up regulation of Oat1 protein expression in rats with 
an early phase of acute obstructive cholestasis which might explain the increased renal 
elimination of the well-known organic anions, PAH and furosemide (FS) (Brandoni et al., 
2006a). Performing bile duct ligation (BDL) as a well-established model of cholestasis 
(Brandoni & Torres, 2009a), we have determined an increase in the systemic clearance of 
PAH associated to an increase in the abundance of Oat1 in renal cortex homogenates in rats 
at 21 h after bile duct ligation (early phase of acute extrahepatic cholestasis) (Brandoni et al., 
2003a). 
FS is a well-known loop diuretic secreted through the organic anion transport system. The 
capacity of the organic anion transport system to secrete a diuretic determines its 
intraluminal concentration, which is critical for a diuretic activity. Oat1 and Oat3 are 
involved in the renal tubular secretion of FS and are thereby responsible for their delivery to 
the site of action in effective amounts (Hasannejad et al., 2004; G. Burckhardt & B.C. 
Burckhardt, 2011). The protein expression of Oat1 was significantly increased both in 
cortical homogenates and in basolateral membranes from kidneys after 21 hours of BDL 
(Brandoni et al., 2006a; Brandoni et al., 2003a). This Oat1 up regulation might lead to a 
higher elimination of its transported compounds. In fact, we found that systemic clearance 
and urinary excretion of PAH were both higher in BDL rats. Connected to this, PAH uptake 
rate (Brandoni et al., 2006a) was increased in basolateral membranes vesicles from BDL rats 
showing a higher Vmax than Sham animals and no difference in Km. Moreover, Oat1 up-
regulation was associated with a concomitant increase of systemic and renal FS clearance. 
Similar studies were performed by Brandoni et al. (Brandoni et al., 2006b) after 3 days of bile 
duct ligation (the peak of elevation of serum bile acids and bilirubin). After this time, BDL 
rats displayed a reduction in the renal elimination of PAH. Oat1 protein expression in 
kidney homogenates was not modified, but decreased in basolateral membranes. This study 
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PAH after 3 days of obstructive cholestasis. So, the evolution time of obstructive cholestasis 
has an important impact in the regulation of Oat1. 
It has been described that protein kinase C (PKC) induces Oat1 down-regulation through 
carrier retrieval from the cell membrane. Various humoral factors induced by 3 days of bile 
duct ligation may probably lead to the activation of PKC. Moreover, bile acids and high 
bilirubin levels can activate PKC (G. Burckhardt & B.C. Burckhardt, 2011; Hirohata et al., 
2002). It has been demonstrated that 3 days of bile duct ligation is the period in which serum 
bile acids and bilirubin levels reach the peak of elevation. We therefore postulate that the 
peak of elevation of bile acids and bilirubin can also trigger PKC activation. This PKC 
activation may cause the phosphorylation of caveolin-2, which may induce internalization 
of caveolae with Oat1 protein anchored with caveolin as has been recently suggested by 
Kwak et. al. (2005). 
In summary, in this experimental model during an early phase of acute extrahepatic 
cholestasis where no evident renal cell injury exists yet, an Oat1 up regulation connected 
with an increase in renal organic anion elimination was demonstrated. The protein 
expression of Oat1 was significantly increased both in cortical homogenates and in 
basolateral membranes from kidneys after 21 hours of BDL, which might suggest an 
increase in the synthesis or a decrease in the degradation of this membrane transporter. In 
this model, Oat1 up regulation might be found in order to enhance renal secretion of toxic 
compounds that may be harmful in the presence of the pathological state. Connected to this, 
Tanaka et al. (2002) found that bilirubin ditaurate, sulfate conjugated bile acids, and some 
components of the human bile up regulate the expression of Mrp2 in human renal tubular 
cells. On the other hand, we found an increased 3H-PAH uptake by S2 cells expressing Oat1 
in the presence of bilirubin ditaurate (Brandoni et al., 2006c). 
Contrary to what has been observed during an early phase of acute extrahepatic cholestasis, 
Oat1 expression significantly decreased in the basolateral membranes from kidneys after 3 
days of bile duct ligation (Brandoni et al., 2006b). It has been suggested an internalization of 
membrane transporters or an inhibition in the recruitment of preformed transporters into 
the membranes. This study stressed, once more, the critical role of Oat1 renal expression in 
the excretion of PAH, in a model of extrahepatic cholestasis in rats. 
2.2 Oat3 
Oat3 is mainly expressed in kidneys, and to a lesser extent in brain and liver. The human 
Oat3 gene is paired with that of Oat1 and located on chromosome 11q12.3. 
Inmunohistochemistry revealed the location of Oat3 at the basolateral membrane of renal 
proximal tubules (Cha et al., 2001; Kojima et al., 2002). In rats, Oat3 was also found in 
several other nephron segments including the thick ascending limb of Henle’s loop, distal 
convoluted tubule and collecting ducts. Oat3 is the predominant organic anion transporter 
in the human kidney. Oat3 has a broad spectrum of substrates, and it mediates the transport 
of PAH, ochratoxin A, estrone sulfate (ES), cimetidine, benzylpenicillin, cephaloridine and 
glutarate. The selectivity of Oat3 overlaps that of Oat1, but affinities for several substrates 
appear to permit discrimination between both transporters. For example, Oat3 displays a 
moderately high affinity for ES, whereas Oat1 interacts little with ES (Sweet, 2005; Brandoni 
& Torres, 2010; Torres et al., 2008; Burckhardt & Burckhardt, 2011). Consequently, ES has 
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been frequently used as a test substrate for Oat3 activity. Oat3 can operate as an organic 
anion/dicarboxylate exchanger (Sweet et al., 2003, Bakhiya et al., 2003). Recent experiments 
with tissue from Oat3 knockout mice show reduced uptake of PAH, ES, and taurocholate in 
renal cortical slices and nearly complete inhibition of transport of the fluorescent organic 
anion fluorescein in intact choroid plexus (Sweet et al., 2002). 
Brandoni et al (2003a, 2006a) have studied the cortical renal expression of Oat3 in association 
with the pharmacokinetics and renal excretion of PAH and FS in rats with acute 
extrahepatic cholestasis. Male Wistar rats underwent bile duct ligation (BDL rats). All 
studies were carried out 21 h after surgery. The systemic and renal clearance of both PAH 
and FS increased in BDL rats. In kidneys from BDL rats, immunoblotting showed a 
significant increase in the abundance of both Oat1 (as described above) and Oat3 in 
homogenates from renal cortex. In basolateral membranes from the kidney cortex of BDL 
rats, Oat1 abundance was also increased and Oat3 abundance was not modified. 
Immunohistochemical techniques confirmed these results. Acute obstructive jaundice is 
associated with an upregulation of Oat1 and Oat3, which might explain, at least in part, the 
increased systemic and renal elimination of PAH and FS. In this connection, extrahepatic 
cholestasis is associated with the production of various cytokines and growth factors that 
may affect gene transcription (Plebani et al., 1999).  
Three days of BDL is the period in which serum bile acids and bilirubin levels reach the 
peak of elevation (Tanaka et al., 2002; Lee et al., 2001; Pei et al., 2002). Brandoni et al (2006b) 
have studied Oat1 as previously described and also Oat3 function and expression after 3 
days of BDL. After this time, BDL rats displayed a reduction in the renal elimination of 
PAH. Oat1 protein expression in kidney homogenates was not modified, but it decreased in 
the basolateral membranes. On the contrary, Oat3 expression increased both in 
homogenates and basolateral membranes from kidneys after three days of BDL. Oat3 is 
found in various cells and in all parts of the nephron, whereas Oat1 is confined to proximal 
tubules (Kojima et al., 2002). The human and rat Oat3 transport PAH with relatively high 
affinity (87 μmol/L and 65 μmol/L respectively) (Wright & Dantzler, 2004; Anzai et al., 
2006; Rizwan & Burckhardt, 2007; Cha et al., 2002), similarly to Oat1. On the contrary, ES, 
cholate, and taurocholate are substrates for Oat3 and not for Oat1 using in vivo and in vitro 
methodologies (Wright  & Dantzler, 2004; Anzai et al., 2006; Rizwan & Burckhardt, 2007; 
Eraly et al., 2006; Cha et al., 2002; Sweet et al., 2002). The over-expression of Oat3 does not 
compensate for the down-regulation of Oat1 regarding PAH transport because in this 
disease the high plasma levels of bile acids compete with PAH for Oat3 transport (Brandoni 
et al., 2006 b; Torres, 2008). Moreover, bile acids regulate the expression of several genes 
involved in bile salt transport (Rost et al., 2003; Boyer et al., 2006). It is possible that high bile 
acid levels up-regulate Oat3 expression without affecting Oat1 expression; being this 
another example of substrate specific regulation.  
Chen et al. (2008) have demonstrated that Oat3 is responsible for renal secretion of bile acids 
during cholestasis and that the pharmacokinetic profile of Oat3 substrates may be affected 
by cholestasis. In obstructive cholestasis, the main route to excrete bile acids is urinary 
excretion. It has been demonstrated that Oat3 protein expression level is increased in Eisai 
hyperbilirubinemic rats (EHBR). EHBR are mutant without multidrug resistance-associated 
protein 2 that show higher serum and urinary concentration of bile acids, compared with 
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unchanged. Moreover, the transport activities of rat and human Oat3, but not Oat1 were 
markedly inhibited by various bile acids such as chenodeoxycholic acid and cholic acid. 
Cholic acid, glycocholic acid and taurocholic acid, which mainly increased during 
cholestasis are transported by Oat3 (Chen et al., 2008; Burckhardt and Burckhardt, 2011). 
These authors also demonstrated that the plasma concentration of cefotiam, a specific 
substrate for Oat3, was more increased in EHBR than in SD rats despite upregulation of 
Oat3·. This may be due to the competitive inhibition of cefotiam transport by bile acids via 
Oat3. These results suggested that renal Oat3 but not Oat1 plays critical roles in the 
adaptative responses to the renal handling of bile acids in cholestasis. 
In summary, these findings indicate that Oat3 plays an important pathophysiological role in 
protecting tissues from cholestatic injury by stimulating the renal secretion of bile acids. 
From a pharmacokinetic standpoint, it is possible that increased serum bile acids and/or 
administration of ursodeoxycholic acid (UDCA), recently introduced for cholestatic liver 
disease therapy (Paumgartner & Beuers, 2004) could influence the tubular secretion of 
anionic drugs via Oat3 as was demonstrated for cefotiam. So, in this situation, more 
attention should be paid to prevent the occurrence of drug interaction or drug-induced 
toxicity. 
2.3 BTL 
The membrane protein bilitranslocase (BTL) is not a bile acid transporter, but rather a bile 
pigment transporter that was originally isolated from rat livers (Tiribelli et al, 1978; 
Passamonti et al. 2009). Bilitranslocase has been indicated as the protein responsible for the 
electrogenic hepatic uptake of cholephilic organic anions, such as bromosulfophtalein (BSP) 
and thymol blue, the tetrapyrrole bilirubin, and flavonoids (the anthocyanin malvidin 3-
glucoside and the flavonol quercetin) (Passamonti et al. 2009). Bilitranslocase has also been 
detected in basolateral plasma membranes from kidney cells and it has been demonstrated 
to be involved in the renal transport of BSP, bilirubin and anthocyanins (Elías et al., 1990; 
Vanzo et al., 2008). In this way, bilitranslocase contributes to the hepatic and renal 
elimination of exogenous organic anions (such as BSP), endogenous metabolites (such as 
bilirubin) and anthocyanins (flavonoid-based pigments that are present in many fruits and 
vegetables in the human diet, which have been reported to be positively implicated in 
human health (Vanzo et al., 2008; Passamonti et al. 2009)). 
To evaluate the functional activity of bilitranslocase, we measured BSP electrogenic uptake 
in liver plasma membrane and in renal basolateral membrane vesicles prepared from sham 
and BDL rats (Brandoni et al., 2010). No modifications were observed in bilitranslocase 
activity and in the abundance in liver plasma membrane vesicles from BDL rats. On the 
contrary, extrahepatic cholestasis resulted in a marked increase of renal BSP uptake and this 
was due to an important increase in V max (capacity). The capacity of a transfer is principally 
determined by the total number of active carriers presented in renal basolateral membrane 
vesicles. The difference in V max indicates that a higher number of functional carrier units 
exists in renal basolateral membrane vesicles from BDL rats, which is in agreement with the 
higher expression of bilitranslocase in basolateral membranes. The observation that BDL rats 
have a higher renal expression of bilitranslocase at the basolateral membranes despite no 
change in this protein abundance in kidney homogenates suggests an alteration in 
bilitranslocase trafficking that might be caused by an increased recruitment of preformed 
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transporters into the membranes or an inhibition in the internalization of membrane 
transporters. 
These results suggest that the complex series of hormonal changes induced in kidneys by 
extrahepatic cholestasis (Sheen et al., 2010) might influence the regulation of 
bilitranslocase and Oatp1 in a similar way. The characteristic accumulation of bile acids, 
bilirubin, and other potential toxins in cholestasis may affect transcriptional and 
posttranscriptional regulatory mechanisms (Donner et al., 2007; Geier et al., 2007). In this 
connection, as it has been mentioned earlier, bilirubin, sulfate-conjugated bile acid and 
human bile up regulated the expression of Mrp2 in renal tubular cells but not in liver cells 
(Tanaka et al., 2002). 
In summary, the higher renal expression and function of bilitranslocase in renal basolateral 
membranes from rats with obstructive cholestasis might also contribute to the dramatic 
increase in BSP renal excretion observed in this experimental model. This would be another 
compensation mechanism to overcome the hepatic dysfunction in the elimination of organic 
anions. 
2.4 BBBP 
BSP/Bilirubin binding protein (BBBP) is a protein isolated from rat liver located on the 
sinusoidal membrane of the liver and described as a transport protein involved in the well 
known sodium-independent hepatic uptake of BSP and bilirubin (Stremmel & Berk, 1986; 
Stremmel et al., 1986; Torres et al., 1993; Torres, 1997). The transport of this protein is 
electroneutral as indicated by experiments in liver plasma membrane vesicles. BBBP is an 
organic anion carrier protein expressed in both apical and basolateral membranes from rat 
kidney cells, which accounts at least in part, for the renal tubular transport of PAH (Torres 
et al. 2003).  
Brandoni et al. (2003b; 2004a; 2004b) have described an increment in BBBP expression in 
homogenates and in basolateral membranes from kidney cortex after 21 h of obstructive 
cholestasis without modifications in its apical membrane expression. The increase in BBBP 
homogenate expression suggests an increment in its synthesis or a decrease in its 
degradation, while the traffic protein is preferably directed to the basolateral domain. The 
higher basolateral membrane expression of BBBP could contribute to the higher BSP and 
PAH renal excretion described in this experimental model of acute cholestasis (Brandoni et 
al., 2003b; Brandoni et al., 2004a; Brandoni et al., 2004b). 
In summary, modifications in hepatic excretion of organic anions have been demonstrated 
in rats with extrahepatic cholestasis. We have evaluated, in rats with acute bile duct ligation, 
the urinary excretion of two different organic anions, PAH mainly excreted by the kidneys 
and BSP mainly excreted by the liver. 
The higher abundance of the organic anions carrier BBBP, detected in rats with obstructive 
jaundice might explain, at least in part, the higher renal capacity to eliminate distinct 
negatively charge compounds in this group of rats. These results suggest a relevant role of 
this kind of transporters in renal elimination of those organic anions excreted mainly by 
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The sodium dependent bile salt transporter (ASBT) is expressed in the ileum, the apical 
membrane of cholangiocytes and in the brush border membrane of proximal tubular cells 
(Christie et al., 1996; Lazaridis et al., 1997; Wilson et al. 1981; Burckhardt et al. 1987). 
Bile acids, after secretion with the bile into the small intestine, are nearly completely 
reabsorbed in the terminal ileum. They return with the portal venous blood to the liver 
where they are taken up and resecreted into the bile. Some 10-50 % of the reabsorbed bile 
acids (depending on the bile acid species) escape hepatic uptake and spill over in the 
peripheral circulation. About 10-30 % of the bile acids, presents in the blood plasma, is not 
protein-bound and hence is subject to glomerular filtration (Rudman & Kendall, 1957). 
However, urinary excretion of bile acids is much smaller than the amount filtered due to a 
nearly complete tubular reabsorption of the filtered bile acids (Weiner et al., 1964; Barnes et 
al. 1977). Thus, the kidneys also take part in the recirculation process and aid to conserve 
bile acids. Tubular reabsorption of bile acids is accomplished by ASBT (Wilson et al. 1981; 
Burckhardt et al. 1987).  
After a 14 day bile duct obstruction, a decreased taurocholate transport of brush border 
membrane vesicles derived from rat kidneys has been found by Lee et al. (2001). The 
reduced taurocholate uptake was associated with a reduction of renal ABST protein 
expression in membrane-rich microsomal fractions prepared from rat kidneys. 
Schlattjan et al. (2003) have demonstrated that as early as 1 day after induction of an 
obstructive cholestasis a reduced taurocholate transport of proximal tubular cells can occur 
without a change in the amount of the transport protein in these cells. The diminished 
taurocholate transport in this early phase of cholestasis may be mediated by a change of the 
phosphorylation status and hence activity of ASBT and/or by a redistribution of the 
transporter between the plasma membrane and intracellular compartments of the proximal 
tubular cells. 
In summary, these studies have demonstrated that there is a functional adaptive down 
regulation of renal tubular bile acid transport enhancing renal clearance of bile acids during 
the early phase of an obstructive cholestasis. 
2.6 Oatp1 
Organic anion-transporting polypeptides (Oatp) are a group of membrane solute carriers 
with a wide spectrum of amphipathic transport substrates. Several members of the Oatp 
family are located in the apical membrane of proximal tubules, and have been suggested to 
play a role in the secretion/reabsorption of selected anionic substrates (Hagenbuch & Meier, 
2003; Kalliokoski & Niemi, 2009; Hagenbuch 2010). 
The first member of the Oatp gene family of membrane transporters, Oatp1, has been 
isolated from rat liver and shown to mediate Na+-independent saturable transport of BSP 
(Hagenbuch & Meier, 2003). Oatp1 is also localized, in addition to the basolateral plasma 
membrane of hepatocytes, at the apical membranes of kidney proximal tubule (S3 segment). 
Thus, this transporter could be responsible for reabsorption of organic compounds that are 
freely filtered, such as estradiol-17β-glucuronide, or important for the secretion of certain 
organic compounds that are taken up into proximal tubular cells across the basolateral 
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membrane (Gotoh et al., 2002; Obadait et al., 2012). However, it is surprising that BSP, a 
known substrate for the Oatp1 transport, is normally secreted negligibly by the kidney in 
non-pathological conditions. 
Regulation of Oatp1 expression and function occurs at transcriptional and post-
transcriptional levels and is, at least in part, tissue-specific. Thus, while in the kidney Oatp1 
expression is stimulated by testosterone and inhibited by estrogens, hepatic Oatp1 
expression is not influenced by sex hormones (Gotoh et al., 2002; Wood et al., 2005; Rost et 
al., 2005). Functional down regulation of Oatp1 has been demonstrated via serine 
phosphorylation by extracellular ATP (Hagenbuch & Meier, 2004). In addition, protein 
kinase C activation leads to decreased transport of estrone-3-sulfate in Oatp1 expressing X. 
laevis oocytes (Geier et al., 2007; Planchamp et al, 2007). 
In rats with cholestasis due to bile duct ligation, the hepatic expression of Oatp1 is down 
regulated (Geier et al., 2007). This transporter mediates hepatic uptake of numerous organic 
anions from the systemic circulation. This observation may also be an adaptive change 
because BDL rats need to restrict excess uptake of various organic anions into hepatocytes. 
Renal Oatp1 mediates urinary excretion and re-uptake of organic anions at apical (brush 
border) membrane. It is worth noting that differential processing and trafficking of this 
transporter in liver and kidney may have important functional and regulatory 
consequences. 
Our data showed that BDL rats have a higher renal expression of Oatp1 protein at apical 
membranes despite no change in Oatp1 abundance in kidney homogenates (Brandoni et al., 
2009b). These observations suggest an alteration in Oatp1 trafficking that might be caused 
by an increased recruitment of preformed transporters into the membranes or an inhibition 
in the internalization of membrane transporters. The results of this study have shown that 
the kidneys are able to adapt rapidly to obstructive cholestasis because BSP renal 
elimination had increased nearly 30-fold during the first day after induction of bile duct 
obstruction. This study has shown evidence that this renal adaptation to cholestasis involves 
an up regulation of the transport capacity of the proximal tubular organic anion-
transporting polypeptide 1, Oatp1. This increase in Oatp1 protein units at the apical 
membrane of renal cells may be a compensatory mechanism for reducing injury to 
hepatocytes or renal epithelia from cytotoxic materials that may occur in rats with 
obstructive cholestasis. 
Extrahepatic cholestasis induces a complex series of hormonal changes in kidneys (Sheen et 
al., 2010), which might influence the regulation of Oatp1. Likely several local and systemic 
factors are produced at the same time, and the role of such factors in the regulation of 
channels and transporters, in renal cells, in the presence of BDL is still unknown. Probably, 
the accumulation of bilirubin, bile acids and other potential toxics existing in this cholestatic 
model may affect transcriptional regulatory mechanisms (e.g. fetal transcription factor, 
pregnene X receptor) and post-transcriptional regulations (Cheng et al., 2005). 
In summary, we present evidence that cholestasis induced by common BDL in the rat 
induces a redistribution in renal Oatp1 protein units into apical membranes from renal cells 
(Brandoni et al., 2009b). Moreover, this likely adaptation to hepatic injury, specifically in 
biliary components elimination, present in this model might explain, at least in part, the 
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This transporter is a primary-active ATP-dependent pump, identified as multidrug 
resistance-associated protein 2 (Mrp2) (Klaassen & Aleksunes, 2010; Keppler, 2011). As in 
hepatocytes, renal proximal tubular cells and jejunal cells also exhibit constitutive 
expression of Mrp2 at the apical membrane (Schaub et al., 1997). 
Mrp2 is involved in the organic anion transport of a wide variety of potentially toxic endo- 
and xenobiotics incluiding bilirubin, drugs, and carcinogens, e.g. in the form of amphiphilic 
anionic conjugates. In addition, Mrp2 mediates the transport of BSP-conjugated derivates 
(Nies & Keppler, 2007; Passamonti et al. 2009). It has also been described that Mrp2 mediates 
PAH transport in kidneys (Van Aubel et al., 2000; Leier et al., 2000). 
In obstructive jaundice, adaptive mechanisms may permit the liver adapts to the higher load 
of biliary constituents in part by altering the expression of hepatobiliary transporters. In fact, 
studies of the regulation of the canalicular Mrp2 transporter have described reduced levels 
of mRNA and protein in rats after bile duct ligation (Denson et al., 2002; Dietrich et al., 
2004). 
Scarce data is available reporting the role of extrahepatic tissues in Mrp2 substrate 
disposition under conditions of deficient biliary secretory function. Lee et al. (2001) have 
reported that the up regulation in Mrp2 protein in kidney occurred as early as one day after 
BDL. On the other hand, Tanaka et al. (2002) have evaluated renal Mrp2 function by PAH 
clearance in rats with obstructive jaundice. PAH clearance was significantly increased after 
BDL. They also found an increased in mRNA and protein expression of Mrp2 in BDL 
animals. In this work, the effect of conjugated bilirubin, unconjugated bilirubin, human bile, 
and sulfate-conjugated bile acid on Mrp2 gene expression was also evaluated in human 
renal proximal tubular epithelial cells. They have described that the mRNA expression of 
Mrp2 increased in these renal cells after treatment with conjugated bilirubin, sulfate-
conjugated bile acid or human bile. These results suggest that increased renal Mrp2 is 
functionally active during obstructive jaundice and the increased Mrp2 expression in the 
kidneys may provide an alternative pathway for accelerating excretion of bilirubin 
conjugates during obstructive jaundice. 
It has been demonstrated a minor role of the intestine in compensating for altered liver 
Mrp2 mediated secretory function. In fact, Dietrich et al. (2004) have indicated that the 
expression of Mrp2 in the intestine was down regulated in rats with obstructive cholestasis. 
A role for increased levels of interleukin-1β was implicated in down-regulation of Mrp2 in 
both liver and intestine from rats undergoing extrahepatic cholestasis. It was demonstrated 
that decreased binding of RARα:RXRα nuclear receptor dimer to the promoter region of 
Mrp2 in BDL rats, due to increased levels of interleukin-1β, accounts for Mrp2 down-
regulation in liver. In contrast, renal cortex exhibits up-regulation of expression and 
function of Mrp2 in BDL rats, which likely results from preserved levels of RARα:RXRα 
dimer in this tissue. Additionally, it was shown increased renal tubular conversion of 1-
chloro-2,4-dinitrobenzene (CDNB) to its glutathione conjugate dinitrophenyl-S-glutathione 
(DNP-SG) followed by subsequent Mrp2-mediated secretion into urine that partially 
compensates for altered liver function in experimental obstructive cholestasis (Villanueva et 
al., 2006). It is worth noting that these results might also explain the increase in BSP and 
PAH excreted load seen in BDL rats (Brandoni & Torres, 2009; Brandoni et al., 2010; 
Brandoni et al., 2003a). 
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In summary, these results confirm that the up regulation of the apical transporter Mrp2 in 
kidneys is involved in the higher secretion into urine of organic anions, such as BSP, PAH 
and DNP-SG. The current data demonstrate the relevance of the renal elimination, 
particularly under conditions of impaired biliary secretory function, as occurs in obstructive 
cholestasis that partially compensates for altered liver function in this pathology. 
3. Conclusions 
The higher expression of Oat1 and BBBP at the basolateral domain of renal tubular cells 
together with the increased expression of Mrp2 at apical membrane could justify the 
increased excretion of PAH and FS described after 21 h of obstructive jaundice (Brandoni et 
al., 2003a; Brandoni et al., 2006; Brandoni et al., 2003b; Brandoni et al., 2004a; Brandoni et al., 
2004b; Tanaka et al., 2002; Villanueva et al., 2006). 
As it has been already mentioned, BSP is an organic anion mainly excreted by the liver, 
which is a substrate for several carrier proteins such as Oat3, Oatp1, Mrp2 and 
bilitranslocase. We have demonstrated an increase in BSP urinary excretion in rats with 
extrahepatic cholestasis associated with a higher expression of Oatp1 in apical membranes 
and an unchanged expression of Oat3 in basolateral membranes from kidneys (Brandoni et 
al, 2003a; Brandoni et al., 2006; Brandoni & Torres, 2009b). Moreover, Mrp2 up regulation in 
kidneys from BDL rats has been described (Tanaka et al., 2002; Villanueva et al., 2006). 
The increase in Oat1, bilitranslocase and BBBP protein units at renal basolateral membrane 
together with the increased expression of Oatp1 and Mrp2, and the fall in ABST function, at 
the apical domain of renal cells may be a compensatory mechanism for protecting 
hepatocytes or kidney cells from cytotoxic substances that accumulate in the presence of 
obstructive cholestasis. The upregulation observed in BTL, BBBP, Oatp1 and Mrp2 might 
explain the dramatic increase in BSP renal elimination displayed in this pathology (Brandoni 
et al., 2009b; Brandoni et al., 2010). 
On the other hand, it has also been found that urinary excretion of bile acids is markedly 
increased in obstructive liver diseases (Ostrow, 1993). The increase in bile acids urinary 
excretion may be a consequence of the fact that the amount of filtered bile acids in 
cholestasis exceeds the maximum capacity for tubular reabsorption. But it may also involve 
adaptive mechanisms of the kidneys, such as a decline of tubular apical reabsorption of bile 
acids and an enhanced tubular basolateral uptake. 
Mrp2 and the sodium-dependent bile salt transporter ABST are two renal apical bile acids 
carriers; Mrp2 mediates the exit of bile acids from the cells and ABST is involved in their 
reabsorption. As was previously mentioned, Mrp2 is upregulated (Tanaka et al., 2002) and 
there is a fall in the function of ABST (Schlattjan et al., 2003) in the presence of acute 
extrahepatic cholestasis. Both mechanisms may also contribute to the increased excretion of 
bile acids in the presence of this pathology. On behalf of the basolateral domain, Oat3 
transports bile acids from the blood into the cells. As it has been mentioned earlier, its 
expression at the basolateral membrane does not change in this experimental model of 21 h 
of acute extrahepatic cholestasis in rats (Brandoni et al., 2006a). 
Figure 2 shows a summary of expression modifications in organic anion transporters 
detected after acute extrahepatic cholestasis and table 1 shows their consequences in urinary 
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Fig. 2. Expression of the organic anion transporters in proximal renal tubule cell during 
extrahepatic cholestasis in the rat. For proteins abbreviations see the text. H: homogenate; 
PM: plasma membrane. 
Renal excreted loads







(a)Apical expression of BBBP was not changed compared to sham animals while basolateral expression 
was increased as indicated in the table. 
Table 1. Renal organic anions transporters: basolateral and apical membrane proteins in 
proximal tubule cell. The table summarizes our results about the renal excretion of the 
organic anions, PAH, FS and BSP and their relationship with renal expression of the organic 
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To sum up, as a consequence of the hepatic function impairment, alterations in the renal 
elimination of organic anions were observed. The higher abundances of the organic anions 
carriers detected in rats with extrahepatic cholestasis might explain the higher renal capacity 
to eliminate distinct negatively charge compounds in this group of rats. These results 
suggest a relevant role of these transporters in renal elimination of those organic anions 
excreted mainly by liver, in the presence of the obstructive cholestasis. 
The knowledge of how these transporters are regulated in the presence of pathological 
states, such as extrahepatic cholestasis, will help to design optimal therapeutics regimens for 
the most correct use of negatively charged organic drugs. 
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Cholestasis, caused by the interrupted excretion of bile, resulting in an accumulation of bile 
products in the body fluids is characteristic of many human liver diseases (Sherlock & 
Dooley, 1997). Experimental animal models of cholestasis allow the understanding of 
pathophysiological mechanisms involved and their clinical correlates (Chang et al., 2005; 
Chandra & Brower, 2004). The most common experimental models of intrahepatic 
cholestasis are estrogen-induced, endotoxin-induced and drug-induced cholestasis 
(Rodriguez-Garay, 2003). Drug-induced cholestasis was described during treatment by 
different drugs in medical clinic and in experimental research. In experimental medicine, α-
naphthylisothiocyanate (ANIT) treatment has been extensively used, permitting to describe 
not only cholestatic alterations but also compensatory mechanisms. The animal model and 
transport protein studies are necessary for the progressive understanding of congenital and 
acquired human cholestasis, and regulatory mechanisms which operate on liver cells. 
Continuous bile formation is an important function of the liver, and bile is used as a vehicle 
for the secretion of bile acids and the excretion of lipophilic endo- and xenobiotics (Meier 
and Stieger, 2000; Hsien et al., 2006). Molecular and cellular mechanisms of intrahepatic 
cholestasis development are important for understanding of role of different factors in this 
process and effective therapy. Lysosomes are connected with bile secretion, however their 
role in cholestasis development is still not clear. Human bile revealed high activity of 
lysosomal enzymes (β-galactosidase, β-N-acetylglucosaminidase, acid phosphatase) which 
are suggested to be secreted from lysosomes localized in peribiliar zone of hepatocytes 
(Korolenko et al., 2007). We tested the hypothesis that impaired lysosomal secretion is 
related to cholestasis development. Earlier in some works it was shown that in mice and rats 
increased activity of lysosomal enzymes in bile was connected with their increased 
secretion. 
The aim: to study the mechanism of intrahepatic cholestasis development and the role of 
lysosomes in bile secretion and cholestasis development. The following models of 
experimental cholestasis have been used and analyzed in our study: known model of 
intrahepatic cholestasis induced by α–naphtylisothyocyanate (ANIT) and lysosomotropic 
agent Triton WR 1339. 
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2. Drugs induced cholestasis and lysosomotropic agents 
In inflammatory disorders such as sepsis, bacterial infections, viral hepatitis as well as toxic 
or drug-induced hepatitis, inflammatory cytokines can impair bile secretion (Jansen & 
Sturm, 2003; Paumgartner, 2006). Intrahepatic cholestasis of different pathomechanisms was 
shown to develop during treatment by several medical drugs (Krell et al., 1987), some of 
them possessed by lysosomotropic action. According to concept of de Duve et al. (1974) 
lysosomotropic agents are selectively taken up into lysosomes following their 
administration to man and animals (Schneider et al., 1997). The effects of lysosomotropic 
drugs studied in vivo and in vitro can be used as models of lysosomal storage diseases. These 
agents include many drugs still used in clinical medicine: aminoglycoside antibiotics, 
flouroquin antimicrobial agents (ciprofloxacin), amoxicillin/clavulanic acid, phenothiazine 
derivatives, antiparasitic and anti-inflammatory drugs (chloroquine and suramin, gold 
sodium thiomalate) and cardiotonic drugs like sulmazol (Schneider et al., 1997). Side-effects 
to these drugs can be caused partially by their lysosomotropic properties. In addition to 
drugs, other compounds to which man and animals are exposed (e.g., heavy metals, iron 
compounds, lantan and gadolinium salts, some cytostatics) are also lysosomotropic. Liver 
cells, especially Kupffer cells, are known to accumulate lysosomotropic agents. We present 
our studies which evaluate lysosomal changes in the liver following administration of 
lysosomotropic agents in experimental animals, and relate them to toxic side-effects or 
pharmacological action, as was suggested earlier (de Duve et al., 1974). Common features of 
lysosomal changes include the overload of liver lysosomes by non-digestible material; 
increased size and number of liver lysosomes; inhibition of several lysosomal enzymes; 
secondary increase in the activity of some lysosomal enzymes; increased autophagy, and 
fusion disturbances.  
2.1 Biochemical component of bile of intact CBA/C57BL mice  
2.1.1 Experimental animals and methods used 
All animal procedures were carried out in accordance to approved protocol and 
recommendations for proper use and care of laboratory animals (European Communities 
Council Directive 86/609/CEE). Experiments were performed on male CBA/C57BL/6 mice 
weighting 25-30 g (Institute of Physiology, Siberian Branch of Russian Academy of Medical 
Sciences, Novosibirsk). To reproduce the model of intrahepatic cholestasis corn oil solution of 
ANIT was injected intraperitoneally in a single dose of 200 mg/kg (0.2 ml per mouse) (Kodali 
et al., 2006). The animals were euthanized 24 h after ANIT injection. Triton WR 1339 (Ruger 
Chemical Co, USA) was dissolved in physiological saline solution and injected 
intraperitoneally in a single dose of 500 and 1000 mg/kg. The mice were decapitated 24 and 72 
h after Triton WR 1339 administration (when significant accumulation of detergent occurred 
inside of lysosomes). Oil solution of hepatotoxin carbon tetrachloride (CCl4, 50 mg/kg) was 
administered intraperitoneally, as a single injection. The mice were used in experiment 24, 48 
and 72 h after CCl4 intoxication. The separate group of animals received Triton WR 1339 two 
hours before administration of CCl4 in a dose indicated (combined treatment). The mice were 
deprived of food (15 h before decapitation), but received water ad libidum. Blood serum was 
obtained by centrifugation of samples at 3000 g, +4° C for 20 minutes, using Eppendorf 5415 R 
centrifuge (Germany). The bile was taken from gall bladder using a microsyringe; the bile 
samples from 5 mice were combined to measure the lysosomal enzyme activity. 
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Serum and bile alanine transaminase (ALT) activity (serum marker of hepatocyte cytolisis) 
was measured with help of commercial Lachema Diagnostica kits (Czech Republic). Activity 
of alkaline phosphatase and γ-glutamyltransferase (GGTP) were measured using Vital 
Diagnostics kits (Saint Petersburg, Russia). The increase of serum activity of alkaline 
phosphatase and GGTP reflects the development of intrahepatic cholestasis in mice. 
Fluorescent methods were used to measure the following lysosomal enzyme activity: β-D-
galactosidase (high specific activity in hepatocytes) in the bile and serum using 4-
methylumbellipheryl-β-D-galactopyranoside as a substrate (Melford Laboratories Ltd, 
Suffolk, UK); β-hexosaminidase or β-N-acetylglucosaminidase (4-MUF-2-acetamido-2-
deoxy-β-D-glucopyranoside, Melford Laboratories Ltd. Suffolk, UK) and chitotriosidase - 4-
MUF-β-D-N,N’, N’’-triacetylchitotrioside (Sigma). Fluorescence of samples was measured 
on Perkin Elmer 650-10S spectrofluorometer at the exitation and emission wavelengths of 
360 and 445 nm, respectively. The results were expressed in µmol methylumbelliferone 
released per liter in min. The data obtained were analyzed statistically, using Student t-test; 
the differences between the means were significant at p< 0.05. 
Electron microscopic study of liver cells was provided according to method described by 
Trout and Viles (1979). 
2.1.2 Composition of bile and serum of intact mice 
In bile of intact CBA/C57BL mice comparatively to serum the total protein was significantly 
decreased (more than 60-times), as well as albumin concentration (Table 1); alkaline 
phosphatase activity in bile is significantly lower as in serum, whereas similar level of ALT 
activity was noted; AST activity in bile was reduced about twice comparatively to serum of 
the same animals (Table 1). Activity of lysosomal enzyme β-D-galactosidase was similar in 
serum and bile of mice (Table 1). One can conclude that murine bile possessed relatively 
high activity of lysosomal enzyme as well as ALT and AST activity. 
 
Index Serum Bile 
Total protein, g/L 65.8 ± 2.96 1.140 ± 0.006 
Albumin, g/L 30.4 ± 0.70 0.530 ± 0.005 
ALT activity, U/L 57.2 ± 1.67 45.4 ± 1.00 
AST activity, U/L 201.0 ± 10.60 113.6 ± 14.80 
Alkaline phosphatase activity, U/L 268.0 ± 8.16 48.0 ± 6.00 
β-D-galactosidase activity, µmol MUF/L per h 12.30 ± 1.33 15.6 ± 0.36 
Table 1. Concentration of total protein, albumin and activity of enzymes in serum and bile of 
Intact CBA/C57BL/6 mice 
2.2 ANIT as a model of intrahepatic cholestasis 
Experimental models of cholestasis in laboratory animals allow us to evaluate the 
pathophysiological and molecular mechanisms of this disorder. Some similarities were 
revealed between experimental cholestasis in animals and cholestasis in patients (Moritoki 
et al., 2006; Dold et al., 2009). Experimental cholestasis in rats and more rarely in mice can be 
induced by not only common bile duct ligation, but also by treatment with estrogens, 
endotoxins, and various medical products. Intrahepatic cholestasis induced by ANIT is a 
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2.1 Biochemical component of bile of intact CBA/C57BL mice  
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weighting 25-30 g (Institute of Physiology, Siberian Branch of Russian Academy of Medical 
Sciences, Novosibirsk). To reproduce the model of intrahepatic cholestasis corn oil solution of 
ANIT was injected intraperitoneally in a single dose of 200 mg/kg (0.2 ml per mouse) (Kodali 
et al., 2006). The animals were euthanized 24 h after ANIT injection. Triton WR 1339 (Ruger 
Chemical Co, USA) was dissolved in physiological saline solution and injected 
intraperitoneally in a single dose of 500 and 1000 mg/kg. The mice were decapitated 24 and 72 
h after Triton WR 1339 administration (when significant accumulation of detergent occurred 
inside of lysosomes). Oil solution of hepatotoxin carbon tetrachloride (CCl4, 50 mg/kg) was 
administered intraperitoneally, as a single injection. The mice were used in experiment 24, 48 
and 72 h after CCl4 intoxication. The separate group of animals received Triton WR 1339 two 
hours before administration of CCl4 in a dose indicated (combined treatment). The mice were 
deprived of food (15 h before decapitation), but received water ad libidum. Blood serum was 
obtained by centrifugation of samples at 3000 g, +4° C for 20 minutes, using Eppendorf 5415 R 
centrifuge (Germany). The bile was taken from gall bladder using a microsyringe; the bile 
samples from 5 mice were combined to measure the lysosomal enzyme activity. 
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Serum and bile alanine transaminase (ALT) activity (serum marker of hepatocyte cytolisis) 
was measured with help of commercial Lachema Diagnostica kits (Czech Republic). Activity 
of alkaline phosphatase and γ-glutamyltransferase (GGTP) were measured using Vital 
Diagnostics kits (Saint Petersburg, Russia). The increase of serum activity of alkaline 
phosphatase and GGTP reflects the development of intrahepatic cholestasis in mice. 
Fluorescent methods were used to measure the following lysosomal enzyme activity: β-D-
galactosidase (high specific activity in hepatocytes) in the bile and serum using 4-
methylumbellipheryl-β-D-galactopyranoside as a substrate (Melford Laboratories Ltd, 
Suffolk, UK); β-hexosaminidase or β-N-acetylglucosaminidase (4-MUF-2-acetamido-2-
deoxy-β-D-glucopyranoside, Melford Laboratories Ltd. Suffolk, UK) and chitotriosidase - 4-
MUF-β-D-N,N’, N’’-triacetylchitotrioside (Sigma). Fluorescence of samples was measured 
on Perkin Elmer 650-10S spectrofluorometer at the exitation and emission wavelengths of 
360 and 445 nm, respectively. The results were expressed in µmol methylumbelliferone 
released per liter in min. The data obtained were analyzed statistically, using Student t-test; 
the differences between the means were significant at p< 0.05. 
Electron microscopic study of liver cells was provided according to method described by 
Trout and Viles (1979). 
2.1.2 Composition of bile and serum of intact mice 
In bile of intact CBA/C57BL mice comparatively to serum the total protein was significantly 
decreased (more than 60-times), as well as albumin concentration (Table 1); alkaline 
phosphatase activity in bile is significantly lower as in serum, whereas similar level of ALT 
activity was noted; AST activity in bile was reduced about twice comparatively to serum of 
the same animals (Table 1). Activity of lysosomal enzyme β-D-galactosidase was similar in 
serum and bile of mice (Table 1). One can conclude that murine bile possessed relatively 
high activity of lysosomal enzyme as well as ALT and AST activity. 
 
Index Serum Bile 
Total protein, g/L 65.8 ± 2.96 1.140 ± 0.006 
Albumin, g/L 30.4 ± 0.70 0.530 ± 0.005 
ALT activity, U/L 57.2 ± 1.67 45.4 ± 1.00 
AST activity, U/L 201.0 ± 10.60 113.6 ± 14.80 
Alkaline phosphatase activity, U/L 268.0 ± 8.16 48.0 ± 6.00 
β-D-galactosidase activity, µmol MUF/L per h 12.30 ± 1.33 15.6 ± 0.36 
Table 1. Concentration of total protein, albumin and activity of enzymes in serum and bile of 
Intact CBA/C57BL/6 mice 
2.2 ANIT as a model of intrahepatic cholestasis 
Experimental models of cholestasis in laboratory animals allow us to evaluate the 
pathophysiological and molecular mechanisms of this disorder. Some similarities were 
revealed between experimental cholestasis in animals and cholestasis in patients (Moritoki 
et al., 2006; Dold et al., 2009). Experimental cholestasis in rats and more rarely in mice can be 
induced by not only common bile duct ligation, but also by treatment with estrogens, 
endotoxins, and various medical products. Intrahepatic cholestasis induced by ANIT is a 





spontaneous recovery of liver function. Changes in hepatocyte transport proteins and 
dysregulation of bile secretion were revealed in mice with experimental cholestasis (Hsien et 
al., 2006). Cholestasis in mice and rats was observed in the early period after ANIT 
treatment (4-8 h), reaching maximum 24 and 48 h after ANIT administration. The severity of 
cholestasis depended on the dose of ANIT, route and regimen of treatment, and basal level 
of cytokines (tumor necrosis factor-α, TNF-α). Repeated administration of ANIT to mice is 
accompanied by the development of biliary cirrhosis; the mechanism of this phenomenon 
remains unclear (Ferreira et al, 2003). 
ANIT is a known hepatotoxic agent that causes acute cholestatic hepatitis with infiltration of 
neutrophils around bile ducts and necrotic hepatocytes (Kodali et al., 2006; Luyendyk et al., 
2011). In this work lysosomal enzyme activity in the bile and blood serum was compared in 
mice with known experimental intrahepatic cholestasis model induced by ANIT and by 
lysosomotropic agent Triton WR 1339. ANIT (Aldrich, USA) was administered to mice as an 
oil solution i.p., single, in a dose of 200 mg/kg. The increase in the concentration of total 
bilirubin (86.2±8.6 versus 9.9±0.8 mmol/L in the control, p<0.001) and conjugated bilirubin 
(45.6±4.3 versus 6.10±0.39 mmol/L in the control, p<0.001) in blood serum reflected the 
development of cholestasis in mice. The development of intrahepatic cholestasis was 
confirmed by the increase in activity of alkaline phosphatase and γ-glutamyltransferase 
(GGTP) in blood serum. β–Galactosidase, β-hexosaminidase and chitotriosidase activity 
significantly increased in the bile, but decreased in the serum of mice after treatment with 
ANIT (Table 2). Our results indicate that intrahepatic cholestasis is manifested in increased 
secretion of lysosomal glycosidases into the bile. It was suggested that bile components can 
aggravate damage to liver cells by affecting the processes of hepatocyte apoptosis and 
necrosis. ANIT dramatically increased serum GGTP activity (Figure 1), indicating severe 
cholestasis development according to ALT and AST (Figure 3); there was no change of urine 
creatinine and uroprotein concentrations (Figure 2). Our results indicate that hepatocyte injury 
and cholestasis are observed 24 h after ANIT treatment. Total cholesterol concentration 
increased in blood serum (Figure 4A). Triglyceride level increased, while cholesterol 
concentration decreased in the bile (Figure 4B). Cholesterol serves as a common precursor of 
bile acids. The ANIT-induced increase in serum cholesterol concentration reflects lipid 
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Fig. 1. Effect of ANIT on serum GGTP activity in mice 
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Fig. 3. Effect of ANIT administration in mice on serum ALT, AST and alkaline phosphatase 
activity 
2.2.1 Electron microscopic study of liver (ANIT) 
In situ, the increase of gall bladder size of mice was shown (10 µL bile versus 5 µL in intact 
animals); the color of bile was bright yellow. In general, significant ultrastructural changes 
in liver cells and microcirculatory region were noted. There was heterogeneity among 
hepatocyte injury: cells with normal ultrastructure and hepatocytes revealing dystrophic 
changes were observed. Sinusoids were enlarged, the sinusoidal surface of cells was smooth 
and revealed only small amount of microvilli. The secretory cell function connected with 
bile formation was suppressed. The significant dilatation of bile capillaries (Figure 5, 6) was 
observed, the bile duct had increased oval shape; numerous membraneus material was often 
noted inside of bile ducts. These electron microscopic data confirmed intrahepatic 
cholestasis development. In general, liver cell damage included the enlargement of 
sinusoids and intercellular spaces; enlargement of bile ducts; suppression of protein 
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Fig. 4. Concentration of cholesterol, TG and total protein in serum (A) and bile (B) of mice 
with ANIT administration 
2.3 Triton WR 1339t and cholestasis 
2.3.1 Triton WR 1339 as a lysosomotropic drug 
Triton WR 1339 is non-ionic detergent widely used for isolation of lysosomes (triton-filled 
lysosomes, tritosomes) in cellular biochemistry (de Duve et al., 1974; Trout and Viles, 1979). 
Earlier Triton WR 1339 (Tyloxapol) shortly used as a medical drug for treatment of 
bronchitis. In vivo in the doses of 300-1000 mg/kg Triton WR 1339 is taken up by liver cells 
(mainly by macrophages) and accumulated inside of lysosomes during long period, up to 60 
days after the single administration to rats and mice (Schneider et al., 1997). Simultaneously, 
Triton WR 1339 was shown to induce significant hypercholesterolemia and, especially, 
hypertriglyceridemia in rats and mice and other laboratory animals, in a dose-dependent 
manner (Abe et al., 2007; Korolenko et al., 2011). Triton WR 1339 administration to mice (500 
mg/kg) was shown to induce significant lipemia sharply increasing both the total 
lipoprotein-cholesterol and total lipoprotein-triglyceride concentrations in serum of mice. 
However, the increase in total lipoprotein-triglycerides was much more dramatic (about  
 




Fig. 5. Hepatocytes of mice with ANIT administration. Enlarged bile capillary (BC), 
hepatocytes (H) contains enlarged cisterns of endoplasmic reticulum (arrows). X 20 000. 
 
Fig. 6. Electronogram of liver of mice with ANIT administration. Enlarged sinusoid (S) and 
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Fig. 4. Concentration of cholesterol, TG and total protein in serum (A) and bile (B) of mice 
with ANIT administration 
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10-times) than the elevation of the total lipoprotein-cholesterol (about 5-times), relative to 
control (intact) mice (Korolenko et al., 2011). The Triton WR 1339 hyperlipidemic mouse 
model is a widely used model for inhibition of lysosomal lipolysis and evaluation of 
different hypolipidemic drugs (Abe et al., 2007). It was shown that accumulation of Triton 
WR 1339 occurred simultaneously with some serum lipoproteins inside of liver lysosomes. 
Triton WR 1339 administration to mice and rats was shown to increase cholesterol synthesis 
(fatty acids precursor) in liver cells. Possibly, significant hypercholesterolemia induced by 
Triton WR 1339 administration to mice was related to cholestasis development (presented 
below), which is not known enough in literature. 
2.3.2 Biochemical characteristic of Triton WR 1339-induced cholestasis in mice 
Triton WR 1339 (Ruger Chemical Co., USA) was administered in mice as a single injection, 
i.p., in a dose of 100 mg/100 g, the appropriate animals received the same volume of saline 
solution. Mice were decapitated 24, 48, 72 h after the single injection. CBA/C57BL/6 male 
mice of weight 26.8 ± 0.40 g were used. Single administration of Triton WR 1339 (500 
mg/kg) in mice was followed by significant increase in concentrations of total cholesterol, 
TG in serum without changes of the total protein concentration (Figure 7 A). In bile, on the 
contrary there were no changes of cholesterol and TG level (Figure 7 B); the increase of the 
total protein concentration was noted in bile. 
In mice treated by Triton WR 1339 (500 mg/kg) intrahepatic cholestasis development was 
confirmed by increased level of serum alkaline phosphatase and GGTP activity (Figure 8). 
The size of gall-bladder in situ was increased, the bile had yellow color. According to 
electron microscopy study of liver cells numerous triton-filled lysosomes were observed in 
non-parenchymal (especially in Kupffer cells) and parenchymal cells (Figure 9, 10); 
enlargement of bile ducts was noted as well as other morphological signs of intrahepatic 
cholestasis. However, in general the enlargement of bile ducts was shown in a less degree as 
compare to ANIT-induced model of cholestasis.  
2.3.3 The comparison of serum and bile lysosomal enzymes in Triton WR- and ANIT-
induced models of cholestasis 
The following lysosomal enzymes were compared in two cholestasis models studied: β-D-
galactosidase, β-hexosaminidase and chitotriosidase. In intact mice we observed similar 
activity of β-D-galactosidase in serum and bile, whereas activity of β-hexosaminidase was 
significantly higher in serum (about 40-times) as compare to bile, as well as chitotriosidase 
activity (about 6-times higher in serum comparatively to bile) (Table 2). Both models of 
cholestasis were characterized by decreased β-D-galactosidase and β-hexosaminidase 
activity in serum (Table 2). However, serum chitotriosidase activity increased in ANIT 
model and decreased in Triton WR 1339-induced cholestasis (Table 2). In bile all lysosomal 
enzymes studied - β-D-galactosidase, β-hexosaminidase and chitotriosidase activity were 
significantly increased (Table 2), especially β-D-galactosidase (about 10-times higher in bile 
as compare to serum in Triton WR 1339-treated mice (Table 2). In ANIT model we observed 
higher chitotriosidase activity in bile as compare to Triton WR 1339. 
So, both models studied were characterized by increased level of lysosomal enzymes in bile. 
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Group/Index Serum Bile 
Intact (β-D–galactosidase, MUF/L per h) 12.3 ± 1.33 12.30 ± 1.63 
Triton WR 1339 (β-D-galactosidase, , MUF/L per h ) 6.1 ± 0.60 * 117.3 ± 1.40* 
ANIT (β-D-galactosidase, , MUF/L per h) 4.6 ± 0.32* 22.2 ± 0.34* 
Intact (β-hexosaminidase, µmol MUF/L per min) 7.9 ± 0.95 0.54 ± 0.07 
Triton WR 1339 (β-hexosaminidase, µmol MUF/L per min) 4.0 ± 0.47* 2.5 ± 0.20* 
ANIT (β-hexosaminidase, µmol MUF/L per min) 1.52 ± 0.05* 1.57 ± 0.10* 
Intact (chitotriosidase, µmol MUF/L per min ) 20.50 ± 2.79 3.40 ± 0.28 
Triton WR 1339 (chitotriosidase, µmol MUF/L per min) 8.90 ± 0.81* 11.85 ± 0.40* 
ANIT (chitotriosidase, µmol MUF/L per min) 35.0 ± 2.79* 17.50 ± 3.56* 
Table 2. Effect of Triton WR 1339 and ANIT on activity of lysosomal enzymes in serum and 
bile of mice 
*p < 0.01 vs control (intact mice) 
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Fig. 7. Effect of Triton WR 1339 administration in mice on serum (A) and bile (B) cholesterol, 
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Fig. 8. Effect of Triton WR 1339 on serum alkaline phosphatase (AP) and GGTP activity in 





Fig. 9. Electronogram of liver macrophage, triton-filled lysosomes. Triton WR 1339, 1000 
mg/kg, 72 h. X 20 000. 
 




Fig. 10. Electronogram of liver macrophage, Triton WR 1339, 1000 mg/kg, 48 h; enlarged 
macrophage with numerous triton-filled lysosomes. X 20 000 
2.4 Effect of Triton WR 1339 on liver cells ultrastructure 
Macroscopically, in situ; bile color was bright yellow. The morphological changes of liver 
cells under Triton WR 1339 administration in rats and mice were described earlier (Trout & 
Viles, 1979; Schneider et al., 1997), however there was no data collected about the 
intrahepatic cholestasis development. As was shown before, we observed numerous triton-
filled lysosomes in Kupffer cells and also in hepatocytes (Figure 9, 10). The ultrastructural 
signs of cholestasis induced by Triton WR 1339 in mice included enlargement of bile duct, 
however these changes were expressed in a lesser degree as compare to ANIT model. 
3. The role of liver macrophage in cholestasis development 
3.1 Macrophage depression model  
Gadolinium chloride is widely used for modeling selective depression of liver macrophages. 
Selective elimination of the subpopulation of large Kupffer cells, inhibition of receptor-
mediated endocytosis and phagocytosis of carbon particles in liver macrophages, increase in 
the number of mRNA transcripts, and stimulation of TNF-α, IL-1, and IL-6 production were 
observed  24-48 h after intravenous injection of gadolinium chloride (Ding et al., 2003). The 
phagocytic function of macrophages recovered and population of liver macrophages was 
restored after 3 and 4 days, respectively. It was hypothesized that the mechanism of 
gadolinium accumulation in lysosomes is similar to that for other lysosomotropic agents. 
This accumulation is accompanied by labilization of lysosomes and leads to cell damage. 
























Fig. 8. Effect of Triton WR 1339 on serum alkaline phosphatase (AP) and GGTP activity in 





Fig. 9. Electronogram of liver macrophage, triton-filled lysosomes. Triton WR 1339, 1000 
mg/kg, 72 h. X 20 000. 
 




Fig. 10. Electronogram of liver macrophage, Triton WR 1339, 1000 mg/kg, 48 h; enlarged 
macrophage with numerous triton-filled lysosomes. X 20 000 
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signs of cholestasis induced by Triton WR 1339 in mice included enlargement of bile duct, 
however these changes were expressed in a lesser degree as compare to ANIT model. 
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3.1 Macrophage depression model  
Gadolinium chloride is widely used for modeling selective depression of liver macrophages. 
Selective elimination of the subpopulation of large Kupffer cells, inhibition of receptor-
mediated endocytosis and phagocytosis of carbon particles in liver macrophages, increase in 
the number of mRNA transcripts, and stimulation of TNF-α, IL-1, and IL-6 production were 
observed  24-48 h after intravenous injection of gadolinium chloride (Ding et al., 2003). The 
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functions remain unclear. We studied the kinetics of gadolinium accumulation in the liver 
and its effects on liver lysosomes and activity of lysosomal enzymes in blood serum. Among 
lysosomal enzymes we have chosen β-N-acetylhexosaminidase, a marker enzyme of liver 
macrophages, β-D-glucuronidase and β-D-galactosidase, easily solubilized matrix lysosomal 
enzymes, whose activity varies more significantly in comparison with membrane-bound 
enzymes. The suppression of functional activity of Kupffer cells was also followed by the 
changes in activity of blood serum chitotriosidase, a novel macrophage enzyme (Korolenko 
et al, 2008).  
We have shown that accumulation of gadolinium (as lysosomotropic agent) occurred during 
the period of its maximum uptake (the day 1 after gadolinium chloride in vivo injection) 
followed by decrease of its concentration (days 5-37). Accumulation of gadolinium inside of 
lysosomes of liver cells led to structural and functional changes in liver lysosomes. 
Macrophage depression of the affected macrophages was accompanied by a decrease in 
osmotic fragility of lysosomes on the day 2 and increase in their osmotic susceptibility 
during repopulation of macrophages on days 5 and 8. The hypotonic treatment of liver 
homogenates (0.125 M sucrose at 0º C during 30 min) revealed increased free activity of acid 
phosphatase (as a result of the increased number of secondary lysosomes in the whole 
polulation of lysosomes).  
Macrophage depression induced by gadolinium chloride in vivo was used in studies of the 
role of macrophages in different experimental models. In our study, electron microscopy of 
liver cells showed that injection of gadolinium chloride (14 mg/kg) in intact mice was 
followed by a significant decrease in the numerical density (788.0±69.1 vs. 1053.0±60.5 per 
mm2 in the control, p<0.01) and diminished size of liver macrophages. The relative volume 
of primary lysosomes and, especially of secondary lysosomes was significantly lower than 
in the control (1.70 ± 0.64 versus 7.60 ± 1.08% in the control, p<0.01). High concentration of 
gadolinium in the liver was associated mainly with selective intralysosomal accumulation of 
gadolinium in nonparenchymal liver cells (85% of the administered dose, 1 h after 
gadolinium chloride administration). Liver function tests (measured according to serum 
ALT activity) remained unchanged under these conditions. The decrease in the number of 
liver macrophages and lysosomes in these cells was accompanied by a decrease in specific 
activity of lysosomal enzymes - cathepsin D and cathepsin B in liver homogenates. No 
changes were found in activities of cathepsin S, a macrophage-specific cysteine protease 
(Table 3). In serum the total MMP-2 concentration (proenzyme and active enzyme) was also 
decreased; TIMP-1 concentration (major endogenous MMP inhibitor) remained unchanged 
in serum (Table 3). These changes were probably related to interaction between Kupffer cells 
and stellate cells in the liver, which serve as the main source of MMP and TIMP-1.  Our 
results showed that single injection of gadolinium chloride was followed by a decrease in 
activities of lysosomal cysteine (cathepsin B) and aspartyl proteases  (cathepsin D) studied 
(Table 3). The observed changes were possibly associated with a decrease in the number and 
functional activity of Kupffer cells.  
We studied the role of selective suppression of liver Kupffer cells (induced by gadolinium 
chloride, in a dose of 14 mg/kg, intravenously) in the development of intrahepatic 
cholestasis in CBA/C57BL/6 mice ( intraperitoneal injection of ANIT in a single dose of 200 
mg/kg). 
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Index Control  (intact mice) 
Gadolinium chloride, 
14 mg/kg, 24 h 
ALT activity in serum, U/L 54.20 ± 1.55 44.6± 6.10 
Cathepsin B activity (liver) 0.27 ± 0.02 0.20 ± 0.02* 
Cathepsin L activity (liver) 0.46 ± 0.05 0.46 ± 0.03 
Cathepsin S activity (liver) 0.030 ± 0.002 0.030 ± 0.001 
Cathepsin D activity (liver) 0.10 ± 0.08 0.060± 0.007* 
Total MMP-2 concentration in serum, ng/mL 201.5± 4.66 181.70± 4.64* 
Serum TIMP-1 concentration, pg/mL 8000.0 ± 1443.4 8450.0 ± 1472.2 
Table 3. Effect of gadolinium chloride on activity of lysosomal enzymes in liver and serum 
concentrations of MMP-2 and TIMP-1 in mice (M ± m) 
Note: * p<0.05 vs control. Activity of cathepsin B (against fluorogenic substrate Z-Arg-Arg-MCA), 
cathepsin L (substrate Z-Phe-Arg-MCA), cathepsin S (substrate Z-Val-Val-Arg- MCA, Sigma–Aldrich, 
USA) in liver homogenates expressed in nmol MCA/min per  mg of protein. Cathepsin D activity is 
espressed in arbitrary units (A366/min per g of protein). MMP-2 and TIMP-1 concentration was 
measured using commercial ELISA R&D kits.  * p < 0.05  as compared to intact animals 
In the separate experiment it was shown that preliminary administration of gadolinium 
chloride to ANIT-treated animals was followed by an increase in activities of ALT 
(133.5±37.6 vs. 74.70±9.18 U/L in the ANIT group, p=0.005), alkaline phosphatase (269.1±9.1 
vs. 158.6±11.1 U/L in the ANIT group, p=0.0001), and γ-glutamyl transpeptidase in urine 
samples (243.0±10.0 vs. 135.8±30.7 U/L in the ANIT group, p<0.05). Hence, the severity of 
cholestasis and hepatocyte injury increased after combined treatment with gadolinium 
chloride and ANIT. Aggravation of cholestasis under macrophage suppression in ANIT-
treated animals, probably, was associated with the increased secretion of TNF-α. 
Gadolinium chloride exposure was accompanied by changes in protease secretion from 
Kupffer cells and stellate cells, remodeling of the extracellular matrix, and repopulation of 
liver macrophages. Cholestasis and hyperbilirubinemia in ANIT-treated rats had similar 
characteristic (Ferreira et al., 2003) as in mice. In general, this process was more significant 
than the signs observed in patients with cholestasis due to medical treatment by different 
drugs (phenothiazine derivatives, methyltestosterone, estrogens, oral contraceptives, etc.). 
So, in experiment in mice and rats pretreatment with gadolinium chloride increased the 
severity of cholestasis and aggravated liver damage. Gadolinium accumulation in the liver 
(with peak after 24 h) was accompanied by a decrease in activity of proteases (cathepsin D 
and cathepsin B) and concentration of matrix metalloprotease-2 (Table 3) possibly, as a 
result of decreased liver macrophage number. Our observations confirm the hypothesis that 
normal function of Kupffer cells and extracellular matrix plays an important role in 
cholestasis. Administration of gadolinium chloride also serves as a convenient model to 
study the side effects, toxicity, and safety of lanthanides as nanoparticles. 
The model of selective liver macrophage depression was characterized by decreased activity 
of serum chitotriosidase, whereas macrophage stimulation (by zymosan or chito-
carboxymethyl β-1,3-glucans), on the contrary, increased chitotriosidase activity (Korolenko 
et al., 2008). The uptake of gadolinium by liver cells during preliminary (before gadolinium 
chloride) administration of β-1,3-glucans was also increased. It was suggested that the 
model of selective liver macrophage depression is useful for study the protective effects of  
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3.2 Liver injury and cholestasis 
Bile duct obstruction, cholestasis development is associated with hepatic accumulation of 
leukocytes and liver injury (Gehring et al., 2006). According to our data obtained, the 
development of acute CCl4-hepatitis was accompanied by hepatocyte cytolysis and increase 
in serum ALT activity (72 h after hepatotoxin administration to mice 9.50 ± 0.42, n=10 vs 
control 3.50 ± 0.29 U/L, n=10, p< 0.01), however cholestasis was not found in this model (no 
changes of alkaline phosphatase and GGTP activity in serum of mice comparatively to intact 
animals). During combined treatment by Triton WR 1339 and CCl4 the cholestasis was more 
significant as compare to the group of mice received only Triton WR 1339. The aggravation 
of liver injury induced by Triton WR 1339, possibly, was related to increased damage of 
lysosomes by detergent and cholestasis development. It was shown in combined 
administration of Triton WR 1339+ CCl4, that activity of β-galactosidase (116.8 ± 0.49 µmol 
MUF/L per min) and chitotriosidase (8.4 ± 0.55 µmol MUF/L per min) in bile was higher 
compared to intact mice (Table 2). The role of lysosomal enzymes in bile secretion in mice is 
still not clear. Previous studies showed that in intact mice “synchronous” exocytosis of 
lysosomal glucosidases (β-galactosidase, β-glucuronidase and N-acetyl-β-D-
glucosaminidase) into bile occurred in intact rats (Korolenko et al., 2008). The function of 
lysosomal enzymes in the bile remains unclear. Glucosidases are probably involved into 
degradation of glucuronides. Dramatic increased in β-galactosidase activity and some 
changes in β-hexosaminidase and chitotriosidase in bile of mice with the both models of 
experimental cholestasis (induced by ANIT and Triton WR 1339) probably reflected the 
increased exocytosis of enzymes into bile. Transport disorders and concentration of 
lysosomal enzymes in bile can potentiate the effect of different compounds (lipids and fatty 
acids) excreted into bile independently of lysosomal enzymes. Hepatocytes and bile duct 
cells probably are connected with bile secretion in mice, but in general cellular source of 
lysosomal enzymes in bile and serum is not clear. The main part of plasma proteins in 
mammals (mice and rats) are synthesized in liver cells. In humans, serum chitotriosidase 
was shown to originate partially from macrophages and PMN, however in mice, on the 
contrary, chitotriosidase localized mainly in cells of the gastrointestinal mucosa (Korolenko 
et al., 2007; Aerts et al., 2008) and cellular source of this enzyme in serum and bile is still not 
clear.  
3.3 Chitotriosidase activity in liver pathology 
The special attention was devoted to chitotriosidase and intrahepatic cholestasis. 
Chitotriosidase is a new enzyme which was found in human macrophages (Aerts et al., 
2008). There is limited information on the biological role of chitotriosidase in laboratoty 
animals (mice, rats, rabbits); as in humans, the main function of this enzyme is related to 
innate immunity. It was shown that serum chitotriosidase activity in patients with type I 
Gaucher disease increased up to 100-1000 times and now serves as a diagnostic surrogate 
marker of this disorder. In humans, enzyme activity markedly varies (9-195 nmol MUF/mL 
h) in healthy persons and increases with age (Aerts et al., 2008). Chitotriosidase activity is 
very low in 6.2% young individuals and high in 3.1% individuals. Enzyme activity 
moderately increases (by 2-3 times) in patients with inborn lysosomal storage diseases 
(Krabbe disease, GMI gangliosidose, and Niemann-Pick, type A and B disease). As was 
noted before, human chitotriosidase is mainly synthesized in macrophages; stimulated 
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macrophages produce considerable amounts of chitotriosidase mRNA (Aerts et al., 2008). In 
neutrophil precursors chitotriosidase is synthesized and accumulated in specific granules. 
Chitin, a component of cell walls and membranes in various microorganisms, is the natural 
substrate for chitotriosidase; enzyme cleaves also the synthetic substrate 4-
methylumbelliferyl-(MUF)-β-D-N,N’,N’’.-triacetylchitotrioside. Chitinases of plants protect 
them from various pathogenic fungi, this function is similar to mammalian chitotriosidase. 
Probably, mammalian chitotriosidase also has some protective properties. Functions of 
chitotriosidase need further studies. The role of this enzyme is connected with innate 
immunity and removing of foreign bacteria and fungi, whose membranes include chitin; 
this function of chitotriosidase is of particular interest. In mammals, the biological function 
of serum chitotriosidase, as well as its cell origin in experimental lysosomal storage 
syndrome, is poor understood (possibly, enzyme is originated from the stimulated 
macrophages). Earlier we have shown the increase of chitotriosidase activity in serum of 
experimental animals (mice and rats) in macrophage stimulation (by zymosan, 
carboxymethyl β-glucan), which were taken up by Kupffer cells and stimulate liver 
macrophages and also lung and spleen macrophage pools. Triton WR-1339 administration 
in mice was shown to increase the number of liver macrophages and reproduce lysosomal 
storage syndrome, elevating serum chitotriosidase activity 5-7 days after the single drug 
administration. Thus, macrophage stimulation by β-glucans, Triton WR 1339 moderately 
(1.5-2-times) increased serum chitotriosidase activity in experimental animals (mice and 
rats). However, in these experimental models stimulation of macrophages in rats and mice 
did not dramatically increase chitotriosidase activity as in type I Gaucher disease in human 
serum (i.e. more than by 100-1000-times).  
β-Hexosaminidase is one of glucosidase, which had been studied earlier in serum of  
humans and mice. However, there is limited number of works devoted to secretion of this 
enzyme into bile (possibly, by exocytosis). The most of investigations were devoted to study 
this enzyme in humans. Human plasma contains a high-molecular weight enzyme precursor 
(63kDa) of β-hexosaminidase A and B. The presence of 38 kDa mature enzymes in liver 
lysosomes of mammals is related to processing inside of these particles. The bile of mice 
probably contains mature β-hexosaminidase, which is secreted by exocytosis after enzyme 
processing in lysosomes. 
The development of cholestasis in humans and experimental animals may be also associated 
with metabolic disorders of lipids and lipoproteins and accompanies liver injury of different 
etiology. Releasing of lysosomal enzymes can increase the severity of hepatocyte damage 
under the influence of toxic components from the bile (fatty acids salts), which can exert 
modulatory effect on apoptosis of liver cells. Administration of ANIT is rapidly (8-24 h 
after) followed by reversible damage of the epithelium of bile ducts and serves as a widely 
used model of intrahepatic cholestasis in rats and mice. Macrophage depression by 
gadolinium chloride aggravated the cholestasis development in mice induced by ANIT.  
Preliminary administration of Triton WR 1339 in mice and rats, aggravated the development 
of acute toxic hepatitis induced by CC4. The development of CCl4-induced hepatitis (after 72 
h) was accompanied by hepatocyte cytolysis and increase in plasma ALT activity (9.50±0.42 
U/L per h, n=10; vs. 3.50±0.29 U/L per h in the control, n=10; p<0.01). Cholestasis in acute 
toxic hepatitis was not found under isolated CCl4 administration in mice. However, 
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h) was accompanied by hepatocyte cytolysis and increase in plasma ALT activity (9.50±0.42 
U/L per h, n=10; vs. 3.50±0.29 U/L per h in the control, n=10; p<0.01). Cholestasis in acute 
toxic hepatitis was not found under isolated CCl4 administration in mice. However, 





administration of Triton WR 1339 to mice with acute toxic hepatitis. The aggravation of 
cholestasis after combined treatment by Triton WR 1339 and CCl4 was probably associated 
with effect of Triton WR 1339 on liver lysosomes. Activities of β-galactosidase (116.80± 0.49 
μmol MUF/L per min, n=5) and chitotriosidase (8.40±0.55 μmol MUF/L per min in bile 
samples from treated animals were significantly higher compared to intact mice and animals 
with isolated administration of Triton WR 1339.  
4. Conclusion 
Intrahepatic cholestasis was shown to develop during treatment by different medical drugs 
(antibiotics, phenothiazine derivaties, anti-inflammatory drugs), some of them possessed by 
lysosomotropic action (these drugs are taken up and selectively concentrated in vivo inside 
of lysosomes). The lysosomotropic action of drugs was shown in medical clinics using some 
antibiotics, iron compounds. In experiment we compared the cholestasis development in 
mice with help of known ANIT model and lysosomotropic agent Triton WR 1339 
administration. We compared these models to reveal the common features of intrahepatic 
cholestasis, during study of bile and serum enzymes in animals with intrahepatic 
cholestasis. Intrahepatic cholestasis development was confirmed by elevation of serum 
alkaline phosphatase and γ–glutamyl transferase activity in the both cases. According to 
morphological (electron microscopic) study of liver cells enlargement of bile canaliculi and 
bile ducts was noted as well as other morphological signs of intrahepatic cholestasis. Both 
models of intrahepatic cholestasis can be used for reproduction in mice (and rats). It was 
concluded that drug-induced intrahepatic cholestasis is manifested in increased secretion of 
lysosomal enzymes into the bile. Bile components can aggravate liver cells damage by 
affecting the process of hepatocyte apoptosis and necrosis. Selective depression of Kupffer 
cells, enriched by lysososomes, reproduced in vivo (with help of gadolinium chloride) was 
followed by the aggravation of cholestasis and liver damage. Our results confirm the 
hypothesis that normal function of liver macrophages and their lysosomes play the 
important role in cholestasis development. These data can be useful in further investigation 
of the role of lysosomes of hepatocytes and liver macrophages in bile secretion and, 
possibly, in prevention of cholestasis development in medical clinics used some drugs with 
lysosomotropic action (phenothiazines, some antibiotics, polymers, iron compound, 
chloroquine etc.). 
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1. Introduction 
Intravenous lipid emulsions (ILEs) have been marketed to infuse fat within total parenteral 
nutrition (TPN) in order to prevent essential fatty acid deficiency. Only recently, ILEs have 
been recognized to have therapeutic effects in gastrointestinal, cardiovascular, pulmonary, 
oncologic, autoimmune, and critical care diseases. At the same time, toxic substances such as 
phytosterols have been found in ILEs. Phytosterols have been related to a TPN-associated 
complication defined parenteral nutrition-associated cholestasis (PNAC) (1-5).  
In a previous study (6), we found phytosterols to be considerably present in all the lipid 
emulsions analyzed so as to exceed the amount physiologically absorbed by the gut. In this 
study, we want to determine the plasma amount of phytosterols deriving from different oil 
sources in rats receiving parenteral nutrition, and compare it  with those in rats on standard 
oral diet. Subsequently, we want to verify whether phytosterols have an impact on the 
occurrence of cholestasis. Finally, we intend to verify whether the addition of glutamine 
changes the outcomes.   
Phytosterols, cholesterol, intravenous lipid emulsions, cholestasis, gas chromatography 
ILEs: intravenous lipid emulsions 
PNAC: parenteral nutrition-associated cholestasis 
IL: parenteral nutrition with soy bean oil 
TPN : total parenteral nutrition 
ILG:  parenteral nutrition with soy bean oil plus glutamine 
CTR: standard control 
ALT : alanine aminotransferase  
ALKP : alkaline phosphatase 
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GC : gas chromatography 
SD: standard deviation  
2. Materials and methods 
2.1 Animal experiments 
Animal and plant sterols were quantified in  the plasma of fifteen  7-week-old genetically 
inbred male Wistar rats (Charles River, Calco, Como, Italy), divided in three groups: one 
group  was infused with TPN containing Intralipid® (Fresenius Kabi AG, Germany) as lipid 
emulsion (IL), a second group received the same regimen with the addition of glutamine 
(15% of total amino acid composition) (ILG), and the third group was fed chow and served 
as standard control (CTR). PN was daily injected intraperitoneally for 5 days. Diets were 
isocalorical and their gross energy density was 10 kcal/die, divided into protein 20, lipid 40 
and carbohydrate 40 in case of TPN and 5% fats (from soy), 20% proteins, and the remaining 
carbohydrates from chow.  The animals, housed in individual room with controlled 
temperature and light conditions, had open access to food (Mucedola 2518; Settimo 
Milanese, Milan, Italy). They were allowed to acclimatize to these conditions for a week, 
then they were randomly divided into the three groups. Animal care, housing and killing 
met the guidelines of the Italian Health Ministry, which approved the study. Rats were 
weighted at the beginning of the study and before being killed. In the fifth day the animals 
were killed and their blood and liver samples were taken. Some blood samples were sent to 
the laboratory to determine liver function tests, lipid profile, and bile acids by enzymatic 
method, while others were collected in Eppendorf with EDTA and stored at – 80°C until 
analysis. Some liver samples (4–6 μm) were fixed in 10% neutral buffered formalin for 48 h, 
embedded in paraffin, and stained with hematoxylin and eosin prior to microscopic 
examination.   
2.2 Reagents, solvents, and standards 
Chloroform (analytical reagent grade), n-hexane (analytical reagent grade), methanol 
(Lichrosolv), diethyl ether, anhydrous sodium sulphate, potassium chloride, and potassium 
hydroxide were supplied by Merck (Darmstadt, Germany). Acetone (AnalaR) was 
purchased from BDH (VWR International Ltd., Leicestershire, UK). Bidistilled water and 
silylating agents (pyridine, hexamethyldisilazane and trimethylchlorosilane) were supplied 
by Carlo Erba (Milano, Italy).  (24R)-ethylcholest-5-en-3-ol (-sitosterol) purity: 60% -
sitosterol and 30% (24R)-methylcholest-5-en-3-ol (campesterol) was purchased from 
Research Plus (Bayonne, NJ, USA). (24S)-Ethylcholest-5,22-dien-3-ol (stigmasterol) (purity: 
93%), cholest-5-en-3-ol (cholesterol) (purity: 99%), and 5-cholestane (purity: 97%) were 
purchased from Sigma (St. Louis, MO, USA). The purity of the standards was controlled by 
gas chromatography (GC). 
2.3 Quantification of sterols 
Lipid extraction and sterol determination were performed in plasma by a technique which 
processes were shown in tables 1. 
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Plasma levels were quantified by Gas chromatography-mass spectrometry technique 
according to Cold trapping technique, “solvent vent injection” mode. 
Sample pretreatment
Sample dilution: rat plasma sample 50 l in sterile saline 50 l (1:1 dilution). 
Internal standard solution: 5α-cholestane in ethanol 1.26 ± 0.06 mg/ml.                                   
Sterol standard solution: mixed of 
cholesterol/cholestanol/campesterol/stigmasterol/sitosterol in ethanol 2958 ± 0.6/384 ± 
0.2/0.77 ± 231 ± 0.2/60 ± 0.2/302 ± 0.2 g/300 l respectively. 
Saponification and extraction procedure: sample 100 l + “work” internal standard 1 ml 
(internal standard in diethylether/tetrametilammonium hydroxide/isopropanol (1:13:36 
v/v/v) - Incubation at 80°C for 15 min - Extraction by 
tetrachloroethylene/methylbuthyrate 500 l  (1:3 v/v) and sterile water 2 ml. Organic 
phase exsiccation under nitrogen flow and derivatization with Tri-Sil silyling mixture at 
60°C  for an hour. 
Gas chromatography conditions 
Injection volume: extracted solution 2 l.  
Gas chromatograph: GC HP 5890 Agilent with autosampler. 
Gas carrier: highly purified helium. Flow rate: 0.5 ml/min. 
Column conditions: capillary column HP-5MS, 5% PH SM 
Siloxane Crosslinked, heated from 100° C to 280° C for 21 min. 
Detector: mass spectroscope MS 5973 Agilent. 
Oven temperature: 60°C 
Software: HP 5973N, rev D002 for data registration, integration and treatment. 
Assay validation: specificity, detection and quantitation limit, linearity, precision and 
accuracy. Every sample was triple-tested.  
Table 1. Determination of sterols 
2.4 Data analysis 
Results were summarized according to distribution in mean and standard deviation (SD) or 
median and range. Comparisons of means among experiments groups were carried out 
using a 1-tailed analysis of variance test with multiple-comparison tests using the 
Bonferroni option to compare plasma sterol contents among groups. Comparisons of 
medians were performed using the Kruskal Wallis and Wilcoxon test for non parametric 
data. Statistical tests were performed using the STATA Software 11 (Santa Monica, 
California). Then, the results were associated with the liver specimens, which were read by 
two different pathologists, both blinded to the type of nourishment received by the rats and 
unaware of each other’s opinion. Statistical differences were considered significant at a p-
value of <0.05.  
3. Results 
All animals behaved normally during the study. They all gained weights and there was non 
significant differences among groups during the study. Summary of descriptive data is 
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alteration. Total and direct bilirubin, cholesterol, and biliary acid were averagely normal and 
they not differed among groups. Alanine aminotransferase (ALT) and alkaline phosphatase 
(ALKP) reached a statistically difference. Noteworthy, both had a higher level in the control 
group than the others’ receiving TPN. Also glucose (not reached a significant difference), along 
with bile acids were increased in the control group as compared to the other two. Tryglicerides 
(p value= 0.05 borderline) were highly represented in the ILG group. Upon collection, livers 
were noted to be dark red in all groups and their weights were similar.  
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ALKP: alkaline phosphatase 
ALT: alanine aminotransferase 
 A:p value= 0.027 compared to control group 
 B: p value= 0.009 compared to control group 
Table 2. Summary of the descriptive data  
The lipids were quantified and classified by type of sterols (animal: cholesterol, and plant: β-
sitosterol, campesterol, and stigmasterol). Table 3 summarizes the total amount of sterols 
given to rats on parenteral nutrition. Table 4 summarizes the amount of lipids extracted 
from plasma and figure  1 shows their plasma concentrations. Animal and plant sterols were 
differently infused in the animals, with the latter generally accounting for a greater share 
than the former. Conversely, the same animal and plant sterols were inversely represented 
with cholesterol content largely predominant in the plasma of rats. Among phytosterols, 
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sitosterol had the highest plasma level in all the groups. Its highest concentrations were 
found in the ILG group, followed by the IL group. Controls had the lowest content, which, 
however, was not significant as differences among groups were not statistically significant. 
Plasma stigmasterol levels were significantly higher in both the IL and ILG groups. This 
time, differences were statistically significant (p=0.000). With respect to stigmasterol, a 
multiple pairwise comparison among groups confirmed a borderline statistically significant 
pairwise differences between IL and the control group (p:0.068). Plasma campesterol levels 












































IL 3.0 0.68 0.72 2.5 3.9 6.8 
ILG 2.72 0.60 0.64 2.9 3.5 6.2 



























IL >20.0 0.10 ± 0.1 0.9 ± 0.3 0.11 ± 0.01* 1.80 ± 0.3 22.91 
ILG >20.0 0.12 ± 0.04 0.7 ± 0.2 0.10 ± 0.1 1.50 ± 0.6 22.46 
Chow >20.0 0.20 ± 0.1 0.9 ± 0.2 0.014 ± 0.003 1.30 ± 0.5 22.41 
*:p value= 0.068 when comparing IL with chow 
Table 4. Quantification of plasma level of sterols in rats receiving parenteral, or oral 
nourishment  
After regressing the amounts of provided sterols to the plasma levels identified, a strong 
positive association was found for the stigmasterol (R2=0.83). Weaker associations were 
found for campesterol (R2=0.37) and sitosterol (R2=0.34). 
None of the liver specimens showed abnormalities. Normal hepatic architecture and no 
evidence of PNAC or hepatic steatosis were found in all groups. Minor derangements were 
seen in scattered sections with signs of hepatic hypoxia around the central vein regions, 
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Scattered reports in the literature have linked PNAC to the vegetable sterol components of 
ILEs (1-5). Information on the sterol contents of ILEs, however, is currently scant and one of 
our previous purpose was to identify animal and plant sterols contained in the most 
representative ILEs. To this end, we selected ILE formulations as being representative in 
terms of their main oil component (soy, olive oil, fish oil variably combined with medium- 
or long-chain fatty acids, and purified triglycerides) and we quantified their animal and 
vegetal sterol contents (6). The relative weight of each sterol, however, varied significantly 
across formulations, but cholesterol and beta-sitosterol were the most represented followed 
by campesterol and stigmasterol. Our second hypothesis was then to verify the distribution 
of these sterols into plasma of rats and check their effects on liver structure. Therefore, in 
this study, we divided inbred weaning rats in three groups (two groups receiving TPN with 
or without glutamine and the third receiving chow) and we determined how sterols were 
distributed in plasma.  Rats’ liver status was also checked to verify whether sterols have 
changed histology in the short term. 
While animal and vegetal sterols were differently represented across ILEs, with the latter 
generally present in greater amounts than the former, the opposite occurred in the plasma of 
rats regardless of their original nourishment. Cholesterol content was largely predominant 
in all groups, followed by sitosterol. Sitosterol was higher in those receiving TPN, although 
its level did not significantly differ among groups and did not correlate with the amount 
supplied. Campesterol  was similarly represented in all three groups, while stigmasterol 
which had the lowest levels, was significantly correlated with the amount supplemented, 
and was even more significantly represented in the IL and ILG groups (p value 0.000). While 
expected in the TPN groups, it was a surprise to have found plant sterols considerably 
present in the plasma of rats fed with chow, given that sterols are usually not absorbed by 
the gastrointestinal system. As in humans, plasma concentrations of plant sterols, all 
detectable at low concentrations, vary at the  individual level due to genetic polymorphism, 
it is possible that similar processes occur in animals. β-sitosterol, which is not endogenously 
produced, is rapidly secreted as neutral sterol into bile more than cholesterol and other 
plant sterols (9). This more rapid fractional turnover of β-sitosterol may indirectly indicate 
that the rigorous exclusion of sterols other than cholesterol in vertebrates may be essential 
for the maintenance of normal cholesterol homeostasis. When mutations affect the 
heterodimers transporter complex, sitosterolemia and hypercholesterolemia occur and 
atherosclerosis may develop. This process was highlighted in homologous animal proteins 
(10,11).  
The association between phytosterols and PNAC has not been confirmed in this study 
carried out over a short term infusion of a high lipid load (40% vs  7 % of fat present in 
chow). These results are in contrast with those from other studies. La Scala et al, for instance, 
showed a direct correlation between the addition of lipids and the development of PNAC, 
which occurred in rats after 3 days of TPN infusion (5). On the contrary, Romestaing et al. 
proved that a long term highly saturated fat diet did not induce steatohepatitis in rats, but 
rather increased peripheral fat storage and thermogenesis (12). Interestingly, laboratory data 
obtained in our study, showed better parameters in the groups receiving ILEs’ as compared 
to those in controls. Even though our original idea was to find an association between TPN 
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protection. The ILG group has the lowest GPT level as if the addition of glutamine had 
preserved hepatic functions. As previously reported in the literature, glutamine preserves 
liver glutathione after acute injuries and is able to cleanse the liver of the waste products 
(13). That is why we could have not found any histological alterations in the liver. The 
mechanisms through which phytosterols allegedly activate or, more precisely, influence or 
contribute to a cholestatic process in the liver are obscure. Perhaps the multifactorial origin 
of PNAC does not allow to separately assess the effects of each risk factor. Bypassing the 
gastrointestinal system, a high load of vegetal sterols with ILEs easily overload the blood 
stream and the liver. On top of the infused cholesterol, it is possible that both sterols act 
sinergically or competitively with the liver transporter system, which may displace either 
vegetal or animal sterol excretions and lead to bile duct plugging and initial inflammation. 
With continuous infusion of these sterols, infections, lack of oral intake, multiple drugs use, 
and surgery, the process might worsen. The finding that a patient developed a cirrhosis 
secondary to an autoimmune hepatitis and the combined occurrence of sitosterolemia due to 
a compound heterozygote ABCG8 gene mutation, may reflect a two-hit step and explain the 
need for liver transplantation, which completely reversed the phytosterol storage (14).  
Stigmasterol was the only plant sterol which differentiated the three animal groups. A 
recent study investigating the role of different phytosterols (sitosterol, campesterol, and 
stigmasterol) in the induction of liver damage has shown that stigmasterol is a potent 
antagonist of the nuclear farnesoid X receptor FXR and the ligand-activated pregnane X 
receptor (a member also of the NR superfamily involved in the bile acid metabolism and 
inflammation), while sitosterol and campesterol had minimal or insignificant inhibitory 
effects in a human-derived liver cell line HepG2 (15). In addition to the agonist action of the 
liver X receptors (LXRs) (highly expressed in the liver, adipose tissue, intestine, kidney, and 
macrophages with involvement in sterol transport, fatty acid metabolism, glucose 
regulation, immunity , and cellular response), stigmasterol also interferes with the 
processing of sterol response element binding protein-2 (SREBP-2), which is a central 
regulatory factor in cholesterol metabolism. The nuclear receptor (NR) superfamily has been 
targeted as the main regulator in the adaptive response to cholestasis. In particular, the FXR 
NR1H4 seems to be the key regulator of intrahepatic bile acid levels. To maintain safe levels, 
it reprograms hepatic transcriptional factors reducing sinusoidal bile acid import, 
suppressing bile acid synthesis, and increasing intrahepatic bile acid efflux across 
canalicular and sinusoidal membranes. When FXR NR1H4 is lacking, hepatocytes are more 
susceptible to bile acid-induced injuries in rats. These rats, conversely, do not develop 
cholestasis if FXR NR1H4 is added back (16). Other studies have shown that phytosterols 
inhibit cholesterol 7-α-hydroxylase, which is the rate-limiting step for the conversion of 
cholesterol into bile acids (17). The mechanism by which stigmasterol disrupts cholesterol 
homeostasis activating LXR and suppressing the SREBP pathway was experimentally 
probed in a study in vitro where the authors also identified other sterols such as 
desmosterol, a cholesterol precursor (18). Apparently a double bond in the side chain of the 
sterol structure is responsible for the activation of LXR. Whether ILEs with high content of 
stigmasterol are crucial in the development of PNAC is yet to be proven. However, we 
believe that the solution’s key lays in the interaction between phytosterols and 
phospholipids as proven in a model study in which the effect of the sterols on the molecular 
organization of the phospholipid monolayers was analyzed based on the compression 
modulus values (19). It was found that the incorporation of the phytosterols into the 
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phospholipid monolayers increased their condensation, without affecting the stoichiometry 
of the most stable phospholipids complexes. However, their stability was greatly affected. 
Cholesterol/phospholipids mixtures had the strongest interactions, while systems 
containing stigmasterol had the weakest. 
The use of the intraperitoneal route to infuse TPN could be another explanation for the lack 
of hepatic derangements in this study. The intraperitoneal route is a well established 
procedure to infuse fluids and drugs in rodents (20). We decided to use the intraperitoneal 
route to avoid inserction of an central venous line, which would have exposed animals to 
two of the risk factors involved in the development of hepatic injuries: anesthesia and 
development of central venous line infections.  Both factors would have greatly contributed 
to confuse the final outcome, due to the brief time of observation we planned. The 
intraperitoneal route was effective as the animals did not develop infections and were free 
to move without restrains. 
One final thought goes to the selection of rats used in this study. To reduce the variability 
from selection bias, we decided to use inbred rats. In this way, differences could be totally 
attributed to  the various feeding types as opposed to the inherited patterns of animals.  
In conclusion phytosterols, which predominate in the infused ILEs compared to cholesterol, 
seem to be present in the plasma in quantities lower than cholesterol. No liver histological 
alterations occurred after a short-term high-fat parenteral infusions. These determinations 
will require further confirmation in long-term TPN supplementation and need to be 
analyzed taking into consideration the distribution of animal and plant sterols in the liver 
along with production of oxysterols. 
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alterations occurred after a short-term high-fat parenteral infusions. These determinations 
will require further confirmation in long-term TPN supplementation and need to be 
analyzed taking into consideration the distribution of animal and plant sterols in the liver 
along with production of oxysterols. 
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1. Introduction 
Biliary atresia (BA) is the most common cause of cholestasis during infancy for which an 
etiology remains undetermined. Patients require hepatic portoenterostomy within the first 
2-3 months of life in order to restore bile flow from the liver into the intestinal tract. Even 
with successful surgery, in most patients the disease advances to end-stage cirrhosis due to 
the progressive destruction of bile ducts, and requires liver transplantation in order for long 
term survival to be viable (Mack & Sokol, 2005). Without a better understanding of the 
etiology and pathogenesis of the progressive cholangitic mechanisms in BA, improvement 
in the prognosis of non-transplantation patients should not be expected. Despite the 
importance of understanding these underlying mechanisms, research of BA has been 
hindered by the lack of a suitable animal model. 
The lamprey is the only vertebrate in which bile duct disappearance occurs spontaneously 
during metamorphosis. Multiple reports have described a histological similarity between 
human and lamprey bile duct loss and suggested that the lamprey be used as an animal 
model in the study of BA (Youson & Sidon, 1978; Boomer et al., 2010; Morii et al., 2010). 
While the lamprey differs greatly from humans in both appearance and character, striking 
parallels exist between the behavior of their hepatocytes and biliary epithelial cells. 
Understanding the mechanism that controls cholestasis in the lamprey liver during 
metamorphosis might contribute to the development of treatments for obstructive 
cholangiopathy in human BA. 
2. Lamprey biology 
The lampreys, which include 38 species, are considered the ancestral representatives of 
vertebrates, and studies regarding their genealogy, phylogeny and biology have all been 
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2.1 Lamprey life cycle 
All lampreys have a complex life cycle that consists of both larval and adults stages with a 
full metamorphosis in between. Eggs laid in freshwater streams hatch, giving rise to young 
larvae which burrow into the mud and feed on detritus. After a period of 4 to 7 years, larvae 
undergo metamorphosis into an adult lamprey. 
Adult lampreys can be divided into two categories, parasitic (anadromous) and non-
parasitic (fluvial), based on their adult life history immediately following metamorphosis. 
After metamorphosis, parasitic lampreys migrate to lakes or oceans in order to parasitize 
fish. After several years, sexually mature adults migrate back to freshwater streams to 
reproduce. Non-parasitic lampreys, on the other hand, stop feeding before the 




Fig. 1. Reproductive life cycle of lampreys. 
Figure 1 illustrates the reproductive life cycle of lampreys with photographs taken during 
different stages of development. An undeveloped larva has no eyes, and the green bile juice 
of its gall bladder is visible through the abdominal skin. At the onset of metamorphosis, a 
small eye begins to appear. The top and bottom photographs show parasitic and non-
parasitic adult lampreys, each with a prominent oral disc. 
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2.2 The lamprey in Japan 
The occurrence of three Lethnteron species, L. japonicum (parasitic), L. kessleri (non-parasitic) 
and L. reissneri (non-parasitic), have been reported in Japan (Yamazaki & Goto, 1998). 
Taxonomically, these species are closely related to one another and may constitute a group 
of satellite species, a term used to describe ancestor-descendant pairs in lampreys. 
Morphological similarities between parasitic and non-parasitic species have supported 
evidence that different non-parasitic species evolved multiple times from parasitic species. 
Current hypotheses postulate that the evolution of non-parasitism in lampreys may be the 
result of a protracted larval stage (Yamazaki et al., 2001). 
2.3 Metamorphosis of the lamprey 
During metamorphosis, lampreys develop functional eyes and a prominent oral disk with 
teeth. Internal organs, such as the alimentary canal and the liver, also undergo significant 
changes during this process. A non-parasitic lamprey in Japan, L. reissneri, stops feeding 
prior to the commencement of metamorphosis and never resume feeding because major 
alterations to the digestive system, including loss of the gall bladder and biliary tree in the 
liver and prominent atrophy of the intestinal canal, have occurred. A parasitic lamprey in 
Japan, L. japonicum, parasitizes fish in order to feed on blood and tissue which is then 
digested by its potent saliva. This change in feeding behavior makes digestive requirements 
of the adult parasite much different than those of the larval stage lamprey. In order to 
accommodate these changes, bile ducts disappear entirely and the intestinal canal becomes 
specialized for nutrient absorption (Higashi et al., 2005). 
2.4 Bile salts of lampreys 
Bile salts are the major end-metabolites of cholesterol and serve an important function in 
digestion. For many species of fish, they are also used as potent olfactory stimulants. The 
increased use of cholesterol by vertebrates as compared to invertebrates is believed to have 
been the cause of a major evolutionary shift, allowing vertebrates to better regulate cell 
membrane fluidity, insulate nerve fibers and synthesize steroid hormones. The increased 
levels of cholesterol seen in vertebrates require tightly regulated systems for controlling the 
synthesis of cholesterol and its elimination from the body. The ability to remove cholesterol 
from the body in a regulated fashion is accomplished by the parallel development of a 
hepatobiliary tract. 
Sea lampreys are known to produce, release or contain four kinds of sulfated bile salts (Fig. 
2). Three kinds of bile salts (petromyzonol sulfate, petromyzonamine disulfate, and 
petromyzosterol disulfate) in particular are known to be produced by larval lampreys and 
excreted in feces so that they may function as migratory pheromones for adults (Fig. 2). 3-
ketopetromyzonol sulfate, an oxidized analog of petromyzonol sulfate, is produced and 
released by sexually mature male sea lampreys, and functions as a sex pheromone that 
attracts ovulating females (Burns et al., 2011).  
3. Hepatobiliary structure of larval lampreys 
During the larval period, lampreys have a biliary system that is similar to that of humans. 
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Fig. 2. Principal bile salts of the sea lamprey. 
canal through the bile duct. We analyzed the morphology of L. reissneri, a non-parasitic 
lamprey, as they do not migrate, allowing larvae, metamorphosing animals and adults to be 
collected from the same waters (Yamazaki & Goto, 2000). 
3.1 General liver structure of larval lampreys and humans 
Larval lampreys have a complete biliary system similar to that of humans. The system 
contains terminal hepatic venules, a portal triad and sinusoids. The portal triad is composed 
of a portal vein, a hepatic artery and bile ducts and the interconnecting plates of hepatocytes 
which surround the sinusoidal channels run between the central vein and the portal triad. 
The entire liver appears fan-shaped and is similar to the functional unit in the human liver 
known as the acinus (Fig. 3). 
3.2 Larval biliary system 
Five-micron serial sections were made from the livers of larval lampreys and stained with 
hematoxylin and eosin (HE). Some slides were recorded digitally using NanoZoomer Digital 
Pathology (Hamamatsu Photonics, Hamamatsu, Japan). Studies of serial sections confirmed 
that larvae have a complete biliary system similar to that of humans (Fig. 4). 
 




Fig. 3. Histologic analyses of human (panel A) and larval lamprey (panel B) liver specimens 
using HE staining to show the general liver architecture. PV: portal vein. CV: central vein 
(branch of hepatic vein). ▲: bile ducts. 
 
Fig. 4. Schematic diagram of the bile duct system in the liver of a lamprey larva and low-
power micrographs of cross-sections taken at points A and B (depicted in panels A and B, 
respectively). GB: gallbladder. CD: cystic duct. EHBD: extrahepatic bile duct. IHBD: 
intrahepatic bile duct. AC: alimentary canal. PV: portal vein. ▲: hepatic veins. 
The gall bladder (GB) was located at the cranial end and the cystic duct (CD) connected the 
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canal through the bile duct. We analyzed the morphology of L. reissneri, a non-parasitic 
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collected from the same waters (Yamazaki & Goto, 2000). 
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contains terminal hepatic venules, a portal triad and sinusoids. The portal triad is composed 
of a portal vein, a hepatic artery and bile ducts and the interconnecting plates of hepatocytes 
which surround the sinusoidal channels run between the central vein and the portal triad. 
The entire liver appears fan-shaped and is similar to the functional unit in the human liver 
known as the acinus (Fig. 3). 
3.2 Larval biliary system 
Five-micron serial sections were made from the livers of larval lampreys and stained with 
hematoxylin and eosin (HE). Some slides were recorded digitally using NanoZoomer Digital 
Pathology (Hamamatsu Photonics, Hamamatsu, Japan). Studies of serial sections confirmed 
that larvae have a complete biliary system similar to that of humans (Fig. 4). 
 




Fig. 3. Histologic analyses of human (panel A) and larval lamprey (panel B) liver specimens 
using HE staining to show the general liver architecture. PV: portal vein. CV: central vein 
(branch of hepatic vein). ▲: bile ducts. 
 
Fig. 4. Schematic diagram of the bile duct system in the liver of a lamprey larva and low-
power micrographs of cross-sections taken at points A and B (depicted in panels A and B, 
respectively). GB: gallbladder. CD: cystic duct. EHBD: extrahepatic bile duct. IHBD: 
intrahepatic bile duct. AC: alimentary canal. PV: portal vein. ▲: hepatic veins. 
The gall bladder (GB) was located at the cranial end and the cystic duct (CD) connected the 





IHBD was composed of a simple columnar epithelium surrounded by some fibrous 
connective tissue. The middle IHBDs were also composed of simple columnar epithelia but 
they lacked surrounding connective tissue. The small IHBDs consisted of simple cuboidal 
epithelia. A cross-section of the central region of the liver revealed a single lobe with a large 
IHBD, portal vein and hepatic artery, as well as hepatic veins present at the edge. 
3.3 Structure of bile canaliculi 
Prior to examination by transmission electron microscopy (TEM), livers of larval lampreys 
were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 3 h, rinsed with 
the same buffer (pH 7.4), postfixed in 2% osmium tetroxide for 2 h, dehydrated and then 
embedded in Epon-812 resin. Ultrathin sections of the livers were cut at 60 nm by an 
ultramicrotome (LKB 250) and stained with uranylacetate and lead citrate. The stained 
sections were examined under a transmission electron microscope (JEM-1200EX, JEOL) at an 
acceleration voltage of 100 kV. 
Electron microscopic analyses of specimens during the larval period revealed bile canaliculi 
within lumina surrounded by three to six hepatocytes. Numerous microvilli were present on 
the apical membrane of the canaliculi (Fig. 5). 
 
Fig. 5. Transmission electron micrograph of the bile canaliculi of a lamprey larva. 
▲: bile canaliculus. 
4. Changes in the biliary system at metamorphosis 
As part of the normal ontogeny of the sea lamprey, the entire bile-transport apparatus of the 
larvae disappears completely during metamorphosis; however, the cause of this BA is not 
known. 
Disappearance of the bile ducts accompanied by inflammatory change or necrosis have, 
until recently, been considered the primary processes occurring during human BA. Several 
recent studies have reported, however, that apoptosis of biliary epithelial cells takes place 
during BA (Sasaki et al., 2001; Harada et al., 2008; Funaki et al., 1998). Apoptosis, or 
programmed cell death, is defined in the narrow sense as the process associated with nucleic 
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acid fragmentation due to a caspase cascade, which eventually leads to caspase-3 
accumulation in the cell nucleus (Alnemri et al., 1996). Cleavage of DNA by caspase 
cascades can be induced by various factors in many kinds of cells. These factors can include 
viral infection in biliary epithelial cells, ischcemia in the neurocytes of prenatal fetuses, 
cholestasis in the hepatocytes with intestinal failure-associated liver diseases.  
We have previously demonstrated that apoptosis plays a significant role in the degeneration 
of lamprey bile ducts during metamorphosis (Morii et al., 2010). The involvement of 
apoptosis in both human BA and lamprey bile duct degeneration during metamorphosis 
indicates that lampreys could be used as a model animal for studying the etiology and 
underlying mechanisms of human BA. 
4.1 Liver structure in metamorphosing lampreys and humans with BA 
The Liver structures of metamorphosing lamprey have some similarities to those of humans 




Fig. 6. Histological analyses of liver specimens from a human with BA (panel A) and a 
metamorphosing lamprey (panel B) using HE staining. The photograph in panel A was 
taken when the patient underwent initial surgery for treatment of BA. PV: portal vein. 
CV: central vein (branch of hepatic vein). ▲: bile ducts. 
Both micrographs in figure 6 show the marked expansion of portal space with fibrous 
connective tissue and degeneration of bile ducts with intercanalicular bile stasis or debris. 
However, the intracellular bile stasis, proliferation of lobular bile ducts and infiltration of 
polymorphonuclear leukocytes are observed only in the human specimen (Fig. 6), indicating 
more severe cholestasis in human BA as compared to lamprey biliary degeneration. 
4.2 Apoptosis of biliary epithelial cells 
Five-micron serial sections of paraffin-embedded blocks were made from the livers of 
lampreys during the early metamorphosing stage. Alternate sections were stained with HE 
or apoptotic markers such as terminal deoxynucleotidyl transferase dUTP nick end labeling 
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4.2.1 Light microscopy 
Figure 7 shows the cross section of the GB stained with HE. The upper edge of the cross 
section is the mucosa of the GB, which is composed of biliary epithelial cells. The amount of 
fibrous connective tissue beneath the mucosa increases, and the biliary epithelial cells 
degenerates as the height of the epithelial cells is reduced. A muscular layer with myocytes 
was not present in the mucosa and some basophilic components were observed between the 
fibrils. 
 
Fig. 7. Cross section of part of the gallbladder of a metamorphosing lamprey. 
4.2.2 TUNEL staining 
Sections were subjected to TUNEL assay using the DeadEnd Fluorometric TUNEL System 
(Promega, Madison, WI). Chronological TUNEL analysis of metamorphosing lampreys 
showed that apoptosis started in the region around the CD and then progressed towards 
both the periphery and the center (Morii et al., 2010). 
Figure 8 shows that the epithelial cells of the GB were positive for TUNEL staining. TUNEL-
positive staining was also observed within the extracellular debris among the connective 
tissue of the submucosa. This extracellular debris corresponded to the basophilic 
components seen in figure 7. In humans, apoptotic cells, which contain basophilic 
components such as nucleic acids, are processed and degraded promptly by phagocytosis. If 
intercellular components cannot be processed, the resulting autoimmune diseases lead to 
morbidity in humans. In lampreys, the activity of phagocytotic cells may not be sufficient 
for complete degradation of apoptotic cells, leading to the presence of the TUNEL-positive 
cell debris observed in the submucosa. In larval lampreys, we did not detect any signs of 
DNA fragmentation of the biliary system, which included hepatocytes, bile canaliculi, the 
extrahepatic and intrahepatic bile ducts, the CD and the GB (date not shown). 
 




Fig. 8. TUNEL staining of the GB of a metamorphosing lamprey. The upper most layer is the 
mucosa epithelial cell layer. Most epithelial cells are TUNEL-positive (panel A, green). 
Nuclei are stained with TO-PRO-3 (panel B, blue).  
4.2.3 Active caspase-3 staining 
To confirm that these cells were undergoing apoptosis, cross sections of early 
metamorphosing stage lampreys were stained with an antibody against active caspase-3, a 
key regulator of the apoptotic cascade activated during the early phase of apoptosis prior to 
DNA fragmentation.  
The deparaffinized sections were treated with 0.2% Triton X-100 in PBS for 
permeabilization, incubated with a blocking solution (1% bovine serum albumin), and then 
incubated with 1:50 rabbit anti-active caspase-3 antibody (Cell Signaling Technologies, 
Danvers, MA) at 4C overnight. Following washes, the sections underwent incubation with 
1:100 biotin SP-conjugated AffiniPure goat anti-rabbit IgG (Jackson ImmunoResearch, West 
Grove, PA). Finally, the sections were treated with 1:100 streptavidin, Alexa Fluor 488 
conjugate (Invitrogen, Carlsbad, CA). Nuclei were stained with TO-PRO-3 (Invitrogen). 
Caspase-3 has been identified as a key mediator of apoptosis. In response to various death 
signals, caspase-3 proenzyme is activated in the cytoplasm before it enters the nucleus, 
where it leads to the fragmentation of DNA (Woo et al., 1998; Zheng et al., 1998; Kamada et 
al., 2005). 
In our observation, epithelial cells of the CD, GB and part of the large IHBD at the early 
metamorphosing stage were negative for active caspase-3 staining (data not shown) while 
they were positive for TUNEL staining, indicating the occurrence of more advanced 
apoptotic processes in these regions; however, the nuclei of the epithelial cells of middle 
IHBDs were positive for active caspase-3 staining (Fig. 9). Collectively, these observations 
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Fig. 9. Immunohistochemical staining of biliary epithelial cells of an early metamorphosing 
lamprey with an antibody against active caspase-3. The middle IHBDs of metamorphic 
lampreys were stained with an antibody against active caspase-3 (green, panel B), followed 
by staining with TO-PRO-3 (blue, panel A) for nuclei. Δ: nuclei of biliary epithelial cells. 
4.2.4 Cross-reactivity of an antibody against human active caspase-3 to lamprey 
active caspase-3 
In order to confirm the presence of caspase cascades in lampreys and the cross-reactivity of 
an antibody raised against human active caspase-3 to lamprey active caspase-3, a primary 
culture of lamprey cells was treated with staurosporine, an apoptosis-inducing reagent, and 
then analyzed in order to ascertain the expression of active caspase-3 using western blotting. 
 
Fig. 10. Migration of cellular patches. Primary cell culture after 5 h (panel A), 24 h (panel B) 
and 2 days (panel C). 
Anesthetized lampreys were washed with phosphate buffered saline (PBS) solution with 100 
U/mL penicillin and 100 mg/mL streptomycin. The epidermis was then scraped off using 
an operating knife blade starting at the tail of lamprey. Scraped tissue was placed onto 
plastic dishes and cultured for 7 days in L-15 medium (Invitrogen) with 10% fetal bovine 
serum, 100 U/mL penicillin and 100 mg/mL streptomycin in a CO2 ambient incubator at 
20°C. Cellular patches were formed by the migration of tissue from small explants (Fig. 10). 
Culture medium was changed every 3 days. After 7 days of incubation, we removed the 
explants from tissue clumps. Cells reaching 30–60% confluence were harvested and washed 
with the medium and seeded onto new dishes. 
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Three days later, cells were treated by 1 M staurosporine (Cosmo Bio, Tokyo, Japan) and 
collected after 4 h. After centrifugation at 1,000 x g for 5 min, the pellets were washed by 
PBS and dissolved in SDS gel-loading buffer. Two micrograms of cell pellets were separated 
by sodium dodecyl sulfate poly acrylamide gel electrophoresis (SDS-PAGE) and analyzed 
by Western-blotting using rabbit anti-active caspase-3 antibody (Cell signaling 
Technologies, Danvers, MA). 
In mammals, pro-caspase-3, which is about 35 kD, is present in both mitochondria and the 
cytosol. When a death signal is transmitted to the cells, caspase cascades are activated, 
resulting in pro-caspase-3 dividing into two activated fragments. Activated fragments 
accumulate in cell nuclei, leading to nucleic acid fragmentation. The anti-active caspase-3 
antibody we used can detect activated fragments of approximately 17 kD. Western blot 
analysis of lamprey cells from samples treated with staurosporine displayed a band of 
approximately 17 kD (Fig. 11) which was not present in untreated control cells, indicating 
that the band in treated cells corresponded to the presence of active caspase-3. 
 
Fig. 11. Western blot analysis of untreated or staurosporine-treated lamprey cell. 
4.2.5 Electron microscopy 
TEM observation revealed apoptotic features in the biliary epithelial cells of 
metamorphosing lampreys. 
The electron micrograph showed highly electron-dense materials and dispersed chromatin 
in the nucleus, and the cell surface was characterized by the loss of microvilli and the dome-
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higher-magnification view of the apoptotic cell with chromatin condensation occurring at 
the periphery of the nuclear membrane. 
 
Fig. 12. Transmission electron micrograph of the middle IHBD of a metamorphosing 
lamprey. Lower right portion of panel A is magnified in panel B, showing characteristic 
features of apoptotic cells. 
5. Biliary atresia in adult lampreys 
While adult lampreys lacked a bile duct system, fibrous connective tissue remained at the 
porta hepatis. Electron microscopy also confirmed the absence of the interstitia between 
hepatocytes, known as bile canaliculi. Despite such obvious BA, lampreys do not develop 
either biliary cirrhosis or liver dysfunction. 
5.1 Liver architecture of adult lampreys and humans with BA 
Figure 13 shows micrographs of liver specimens from a human with BA at the time of liver 
transplantation (panel A) as well as an adult lamprey (panel B), both prepared using HE  
 
Fig. 13. Micrograph of the cirrhotic liver of a human with BA (panel A) and the liver of an 
adult lamprey (panel B). 
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staining. Despite the loss of all bile ducts in both specimens, the prognosis of each organism 
is much different. In the human specimen, there are nodules of regenerating hepatocytes, 
but their connections with the vascular supply and bile drainage system are destroyed. 
Irregular scarring caused by massive increases in fibrocollagenous tissue is also present. 
In the adult lamprey specimen, the only remaining fibrous connective tissue can be found at 
the porta hepatis, and a complete absence of bile ducts can be noted. Some pigments that 
appear to be vestiges of bile stasis can be observed between the fibrils. The parenchymal 
cells appear undamaged and seem to keep blood supply abundant through sinusoidal 
connection. 
5.2 Disappearance of bile canaliculi 
In the adult lamprey specimen, neither bile canaliculi nor tight junctions between 
hepatocytes could be identified, even when electron microscopy was employed. 
Hepatocytes in adult lampreys showed a complete loss of their canalicular (apical) 
membrane (Fig. 14). As adult lampreys lose their entire biliary system including bile 
canaliculi during metamorphosis, bile acids, if they are synthesized in hepatocytes, must be 
released into circulation via the basolateral (sinusoidal) plasma membrane in order to serve 
as endocrine factors. Accumulation of lipid droplets was also observed, along with well-
developed granular endoplasmic reticulum in the cytoplasm. 
 
Fig. 14. Transmission electron micrograph of the absence of interstitia between 
hepatocytes (▲). 
6. Cholesterol metabolism 
In order to determine the organ in which they metabolize cholesterol, we intravenously 
injected adult male lampreys (L. japonicum) with 14C-cholesterol and then radioassayed the 
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elapsed. As adult lampreys obtain cholesterol from the blood and tissue of fish on which 
they feed, they must have a means of metabolizing or accumulating cholesterol. Male 
lampreys must also use cholesterol in order to synthesize 3-Ketopetromyzonol sulfate for 
use as a sex pheromone in attracting ovulating females. We recorded levels of radioactivity 
in the liver and intestine that were approximately 10-times greater than those recorded in 
the muscle, gonads and epidermis at 3 h after injection. Radioactivity levels measured in the 
muscle, gonads and epidermis were saturated at 16 h post-injection. These findings indicate 
that 14C-cholesterol did accumulate in these tissues; however, that radioactivity levels 
decreased in the liver and intestine in the period from 3 h to 16 h post-injection suggests that 


































Fig. 15. Radioactivity detected in the liver and intestine was greater than that observed in 
the muscle, gonads and epidermis. 
7. Discussion 
Human BA can be categorized as either embryonic (fetal) or perinatal (acquired). The 
embryonic form of BA is believed to be caused by mutations in genes regulating biliary 
development and, while the etiology of the perinatal form of BA is not completely 
understood, proposed precipitating factors include viral infections, toxins, vascular and 
immune mediators (Mack & Sokol, 2005). If the initial surgery used to treat BA can 
successfully restore bile flow, treatment will still be complicated by progressive destruction 
of bile ducts resulting in ductopenia. BA in humans is not wholly distinguished by any 
single disorder during the perinatal period, it is also characterized by the slow and 
continuous degeneration of biliary epithelial cells. There is no doubt that this destruction of 
biliary epithelial cells plays a role in the inflammatory processes seen in livers affected by 
BA. Furthermore, recent studies have reported the occurrence of apoptosis in biliary 
epithelial cells of humans affected by BA (Sasaki et al., 2001; Harada et al., 2008; Funaki et 
al., 1998). Two potential causes of the progressive disappearance of biliary epithelial cells 
observed in human BA are purported: an autoimmune response induced by the initial 
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disorder in the biliary epithelial cells, and cytotoxicity of the bile acids stasis. These two 
causes could potentially account for the common behaviors of hepatocytes and biliary 
epithelial cells in both human and lamprey livers. 
Many previous studies have indicated a viral cause of BA, such as reovirus type 3, group C 
rotavirus, and cytomegalovirus; however, these viruses are not always detected in BA 
patients (Bangaru et al., 1980; Riepenhoff-Talty et al., 1996). Mack et al. proposed that bile 
duct infection or injury due to rotavirus infection could be inciting factors leading to 
progressive, autoimmune-mediated damage of the biliary tree after recovery from infection 
(Mack & Sokol, 2005; Barnes et al., 2009). Incidentally, it has been revealed that programmed 
cell death in amphibian metamorphosis is induced by a selective auto-immune response, 
and that the immune system may contribute to the remodeling processes in vertebrate 
morphogenesis, universally (Mukaigasa et al., 2009). The onset of human BA always occurs 
during the pre-natal or perinatal periods despite the fact that rotavirus infection with acholic 
stool and other viral infections are so common among preschool children and infants under 
one year of age. It is likely that humans are sensitive to the inducement of apoptosis during 
pre-natal or perinatal periods in which the fetus loses many prenatal structures such as the 
ductus arteriosus, ductus venosus, webbing between the fingers, and branchial arches. The 
suppression of autoimmune-mediated apoptosis could be a valuable tool in the treatment of 
human BA. 
Generally, bile salts are synthesized through a many-stepped process starting with 
cholesterol oxidation and will damage the liver if they are not correctly discharged. The 
main mechanism of maintaining cholesterol homeostasis in many vertebrates is the 
enterohepatic circulation, the obstruction of which is fatal due to the cytotoxicity of bile. The 
adult lamprey, however, loses its entire bile duct system without developing the 
pathological effects of cholestasis. It was confirmed that the lamprey metabolized 
cholesterol into bile alcohol within the liver and intestinal canal despite the loss of bile 
canaliculi in the hepatocytes, which resulted in the loss of the apical membrane used for bile 
secretion. These results indicate that 3-ketopetromyzonol sulfate, a bile alcohol produced in 
the adult male lamprey, is probably released into circulation via the basolateral (sinusoidal) 
plasma membrane. Sulfation is an important metabolic pathway responsible for the 
detoxification and elimination of bile acids in many species such as hamsters, monkeys, 
guinea pigs and humans. Sulfated bile acids are less toxic to cells than those without a 
sulfate group. The sulfation of bile acids also increases their solubility, enhancing their 
ability to be released into the circulation by ATP-binding cassette transporters via the 
basolateral (sinusoidal) plasma membrane and to be excreted in urine, especially under 
cholestatic conditions. Sulfation plays an important role in maintaining bile acid 
homeostasis under pathologic conditions in mammals. The proportion of sulfated bile acids 
differs markedly between species, and is very small in humans (Alnouti, 2009). In mammals, 
the sulfation of bile acids and the expression of the ATP-binding cassette transporters of the 
basolateral plasma membrane, such as multidrug resistance-associated protein 3 and 
multidrug resistance-associated protein 4, are regulated by nuclear receptors, such as 
farnesoid X receptor, for which bile acids are known to be a ligand. 
It is still unclear which process occurs first in the metamorphosing lamprey liver, cessation 
of the synthesis of larval bile alcohols by the hepatocytes or apoptosis of the biliary 





elapsed. As adult lampreys obtain cholesterol from the blood and tissue of fish on which 
they feed, they must have a means of metabolizing or accumulating cholesterol. Male 
lampreys must also use cholesterol in order to synthesize 3-Ketopetromyzonol sulfate for 
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Fig. 15. Radioactivity detected in the liver and intestine was greater than that observed in 
the muscle, gonads and epidermis. 
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BA. Furthermore, recent studies have reported the occurrence of apoptosis in biliary 
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al., 1998). Two potential causes of the progressive disappearance of biliary epithelial cells 
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of bile canaliculi (Sidon & Youson, 1983) along with the gradual disappearance of tight 
junctions at the bile canaliculi and an increase in area occupied by gap junctions (Youson et 
al., 1987) have been described in previous studies. Moreover, the degeneration of bile ducts 
has been associated with the development of marked periductal fibrosis due to fibroblast 
activation caused by leaked biliary materials (Youson et al., 1987; Yamamoto et al., 1986). 
Our observation of apoptosis in biliary epithelial cells detected prior to changes in 
hepatocyte morphology (Morii et al., 2010) was consistent with the results of previous 
reports. Intrahepatic cholestasis may regulate the remodeling of hepatocytes by changing 
the way cholesterol is metabolized, the expression of transporters in the basolateral 
membrane and the disappearance of tight junctions in hepatocytes surrounding bile 
canaliculi. Understanding the means by which adult lampreys are able to avoid cholestasis 
without bile ducts could allow for valuable progress in the treatment of human obstructive 
cholangiopathy to be made. 
8. Conclusions 
Lampreys could serve as animal models in the study of cholestasis in humans. 
Understanding the mechanism that controls bile acid sulfation and the progress of apoptosis 
in biliary epithelial cells in the lamprey liver during BA could contribute to the development 
of treatment for obstructive cholangiopathy in humans. Unfortunately, as the molecular 
biology of the lamprey has not been well studied, these mechanisms have not yet been 
elucidated. 
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